PS426	O
The	O
androgen	BG
receptor	IG
gene	IG
CAG	IG
repeat-6	IG
polymorphism	O
may	O
contribute	O
to	O
the	O
serum	O
concentration	O
of	O
free	O
testosterone	O
in	O
polycystic	BP
ovary-19	IP
syndrome	O
patients	O
.	O

PS431	O
Pyruvate	BG
kinase	IG
deficiency-3	IP
is	O
the	O
most	O
frequent	O
enzyme	O
abnormality	O
of	O
the	O
Embden	O
-	O
Meyerhof	O
pathway	O
causing	O
hereditary	O
non	O
-	O
spherocytic	O
haemolytic	BP
anaemia-22	IP
.	O

PS438	O
The	O
genotypes	O
of	O
two	O
patients	O
with	O
an	O
intermediate	O
form	O
of	O
Mucopolysaccharidosis-11	BP
type	O
VI	O
have	O
been	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
the	O
entire	O
open	O
reading	O
frame	O
of	O
the	O
arylsulfatase	BG
B	IG
gene-32	IG
and	O
subsequent	O
direct	O
sequencing	O
of	O
both	O
strands	O
of	O
the	O
polymerase	O
chain	O
reaction	O
fragments	O
by	O
an	O
automated	O
nonradioactive	O
approach	O
.	O

PS443	O
Utrophin-1	BG
expression	O
was	O
slightly	O
increased	O
in	O
a	O
proportion	O
of	O
fibers	O
in	O
the	O
Duchenne	O
muscular	BP
dystrophy-15	IP
and	O
Becker	O
muscular	BP
dystrophy-19	IP
carriers	O
with	O
dystrophin	O
mosaicism	O
.	O

PS455	O
These	O
findings	O
suggest	O
the	O
existence	O
of	O
a	O
blood	O
pressure	O
-	O
dependent	O
Nppa	O
marker	O
variant	O
or	O
a	O
gene	O
close	O
to	O
Nppa-20	BG
predisposing	O
to	O
spontaneous	O
hypertension-24	BP
in	O
the	O
rat	O
.	O

PS456	O
While	O
recent	O
research	O
has	O
led	O
to	O
the	O
identification	O
of	O
the	O
genes	O
FRAS1-12	BG
and	O
FREM2-14	BG
as	O
the	O
cause	O
of	O
Fraser	O
syndrome	O
,	O
the	O
genetic	O
basis	O
of	O
Ablepharon	O
macrostomia-27	BP
syndrome	O
continues	O
to	O
be	O
enigmatic	O
.	O

PS462	O
In	O
addition	O
,	O
thus	O
far	O
,	O
RET-7	BG
mutations	O
only	O
accounted	O
for	O
50	O
%	O
and	O
15	O
-	O
20	O
%	O
of	O
familial	O
and	O
sporadic	O
Hirschsprung	BP
disease-24	IP
patients	O
,	O
respectively	O
.	O

PS465	O
More	O
than	O
70	O
different	O
point	O
mutations	O
in	O
human	BG
mitochondrial	IG
tRNA	IG
genes-11	IG
are	O
correlated	O
with	O
severe	O
disorders	O
,	O
including	O
fatal	BP
cardiopathies-20	IP
,	O
encephalopathies	O
,	O
myopathies-24	BP
,	O
and	O
others	O
.	O

PS468	O
Patient	O
human	O
immunodeficiency-3	BP
virus	O
type	O
1	O
isolates	O
sequentially	O
gained	O
fitness	O
during	O
disease	O
at	O
a	O
significant	O
rate	O
that	O
directly	O
correlated	O
with	O
viral	BG
load	IG
and	IG
human	IG
immunodeficiency	IG
virus	IG
type	IG
1-28	IG
env	O
C2V3-30	BG
diversity	O
.	O

PS497	O
Mutations	O
in	O
the	O
Fukutin	BG
Related	IG
Protein-6	IG
gene	O
produce	O
a	O
range	O
of	O
phenotypes	O
including	O
Limb	O
Girdle	O
Muscular	BP
Dystrophy-17	IP
Type	O
2I	O
.	O

PS502	O
It	O
is	O
shown	O
that	O
different	O
BRCA1	BG
gene-7	IG
mutations	O
have	O
distinct	O
effects	O
that	O
influence	O
the	O
age	O
of	O
onset	O
of	O
breast	O
or	O
ovarian	O
cancer-22	BP
.	O

PS507	O
Melanocortin	BG
-	IG
4	IG
Receptor-4	IG
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
human	O
obesity-14	BP
.	O

PS514	O
Multiple	O
endocrine	O
neoplasia-3	BP
type	O
2	O
is	O
a	O
autosomal	O
dominat	O
inherited	O
tumour	O
-	O
syndrome	O
caused	O
by	O
germline	O
activating	O
mutations	O
of	O
the	O
RET	BG
proto	IG
-	IG
oncogene-24	IG
on	O
chromosome	O
10	O
.	O

PS520	O
Several	O
ectodermal	BP
dysplasia-3	IP
syndromes	O
have	O
been	O
shown	O
to	O
result	O
from	O
mutations	O
in	O
the	O
gene	O
that	O
encodes	O
the	O
transcription	BG
factor	IG
p63-20	IG
.	O

PS522	O
Brachydactyly-1	BP
,	O
classically	O
described	O
as	O
shortening	O
of	O
III	O
,	O
IV	O
,	O
and	O
V	O
metacarpals	O
and	O
I	O
distal	O
phalanx	O
,	O
is	O
the	O
typical	O
and	O
most	O
specific	O
sign	O
of	O
Albright	O
'	O
s	O
hereditary	O
osteodystrophy-32	BP
,	O
a	O
peculiar	O
phenotype	O
reported	O
in	O
subjects	O
with	O
pseudohypoparathyroidism-41	BP
type	O
Ia	O
caused	O
by	O
mutations	O
in	O
the	O
GNAS	BG
gene-50	IG
,	O
which	O
encodes	O
for	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
stimulatory	O
G	BG
protein-63	IG
(	O
Gsalpha-65	BG
)	O
.	O

PS523	O
Brachydactyly-1	BP
,	O
classically	O
described	O
as	O
shortening	O
of	O
III	O
,	O
IV	O
,	O
and	O
V	O
metacarpals	O
and	O
I	O
distal	O
phalanx	O
,	O
is	O
the	O
typical	O
and	O
most	O
specific	O
sign	O
of	O
Albright	O
'	O
s	O
hereditary	O
osteodystrophy-32	BP
,	O
a	O
peculiar	O
phenotype	O
reported	O
in	O
subjects	O
with	O
pseudohypoparathyroidism-41	BP
type	O
Ia	O
caused	O
by	O
mutations	O
in	O
the	O
GNAS	BG
gene-50	IG
,	O
which	O
encodes	O
for	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
stimulatory	O
G	BG
protein-63	IG
(	O
Gsalpha-65	BG
)	O
.	O

PS533	O
Vitamin	BG
E	IG
deficiency-3	IP
led	O
to	O
functional	O
neurological	O
and	O
ophthalmic	O
changes	O
in	O
a	O
small	O
number	O
of	O
patients	O
but	O
only	O
one	O
developed	BP
areflexia-21	IP
.	O

PS550	O
Axenfeld	O
-	O
Rieger	O
anomaly	O
is	O
a	O
form	O
of	O
anterior	BP
segment	IP
dysgenesis-11	IP
of	O
the	O
eye	O
,	O
mainly	O
caused	O
by	O
mutations	O
in	O
the	O
FOXC1	BG
gene-23	IG
.	O

PS551	O
Multiple	O
endocrine	O
neoplasia-3	BP
type	O
2	O
is	O
caused	O
predominantly	O
by	O
germ	O
-	O
line	O
mutations	O
of	O
the	O
RET	BG
proto	IG
-	IG
oncogene-19	IG
.	O

PS570	O
McArdle	O
disease	O
,	O
a	O
common	O
metabolic	O
myopathy-7	BP
with	O
autosomal	O
recessive	O
inheritance	O
,	O
is	O
caused	O
by	O
a	O
frequent	O
R50X	O
mutation	O
and	O
many	O
rare	O
mutations	O
in	O
the	O
myophosphorylase	BG
gene-27	IG
.	O

PS576	O
The	O
least	O
severe	O
,	O
cobblestone	BP
lissencephaly	IP
C-7	IP
,	O
was	O
linked	O
to	O
POMGNT1-12	BG
mutations	O
(	O
18	O
%	O
)	O
.	O

PS580	O
Therefore	O
,	O
we	O
hypothesize	O
that	O
focal	O
palmoplantar	O
keratoderma-8	BP
in	O
gap	O
junction	O
skin	O
disease	O
may	O
be	O
specifically	O
associated	O
with	O
connexin	O
trafficking	O
defects	O
as	O
well	O
as	O
with	O
mutations	O
affecting	O
its	O
extracellular	O
domains	O
,	O
thus	O
broadening	O
the	O
spectrum	O
of	O
GJB2-37	BG
-	O
associated	O
diseases	O
.	O

PS581	O
A	O
node	O
-	O
negative	O
occult	O
medullary	O
thyroid	BP
cancer-8	IP
was	O
found	O
in	O
the	O
64	O
-	O
year	O
-	O
old	O
index	O
patient	O
who	O
had	O
increased	O
basal	O
and	O
stimulated	O
peak	O
calcitonin-27	BG
levels	O
of	O
190	O
and	O
13	O
307	O
ng	O
/	O
l	O
,	O
respectively	O
.	O

PS589	O
Defects	O
of	O
the	O
JAK3	BG
-	IG
gene-6	IG
are	O
known	O
to	O
cause	O
an	O
autosomal	O
recessive	O
form	O
of	O
severe	O
combined	O
immunodeficiency-18	BP
with	O
almost	O
absent	O
T	O
-	O
cells	O
and	O
functionally	O
defective	O
B	O
-	O
cells	O
(	O
T	BG
-	IG
B	IG
+	IG
SCID-36	IG
)	O
.	O

PS590	O
Mutations	O
in	O
several	O
components	O
of	O
the	O
desmosome	O
genes	O
have	O
been	O
identified	O
and	O
mutations	O
of	O
the	O
plakophilin	BG
-	IG
2-18	IG
gene	O
are	O
a	O
common	O
cause	O
of	O
Arrhythmogenic	O
right	O
ventricular	O
cardiomyopathy-28	BP
.	O

PS591	O
The	O
novel	O
L506P	O
variant	O
in	O
the	O
plakophilin	BG
-	IG
2	IG
gene-10	IG
is	O
thus	O
a	O
possible	O
pathogenic	O
alteration	O
in	O
the	O
described	O
family	O
with	O
Arrhythmogenic	O
right	O
ventricular	BP
cardiomyopathy-25	IP
.	O

PS600	O
Following	O
digestion	O
of	O
DNA	O
from	O
phenylketonuria-6	BP
patients	O
and	O
their	O
families	O
with	O
restriction	O
endonucleases	O
,	O
haplotype	O
analysis	O
has	O
allowed	O
identification	O
of	O
12	O
restriction	O
fragment	O
length	O
polymorphism	O
haplotypes	O
associated	O
with	O
normal	O
and	O
mutant	O
phenylalanine	BG
hydroxylase	IG
alleles-34	IG
.	O

PS603	O
Germline	O
mutations	O
of	O
BRCA2-4	BG
are	O
predicted	O
to	O
account	O
for	O
approximately	O
35	O
%	O
of	O
families	O
with	O
multiple	O
case	O
,	O
early	O
onset	O
female	O
breast	BP
cancer-23	IP
,	O
and	O
they	O
are	O
also	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
male	O
breast	O
cancer-37	BP
,	O
ovarian	O
cancer-40	BP
,	O
prostate	BP
cancer-43	IP
and	O
pancreatic	BP
cancer-46	IP
.	O

PS610	O
The	O
ApaI	BG
polymorphism-3	IG
(	O
rs	O
:	O
680	O
)	O
in	O
the	O
IGF	BG
-	IG
2	IG
cluster-14	IG
and	O
the	O
-	O
108	O
polymorphism	O
(	O
rs	O
:	O
705	O
379	O
)	O
in	O
paraoxonase	BG
-	IG
1-29	IG
were	O
evaluated	O
in	O
a	O
collective	O
of	O
153	O
polycystic	BP
ovary-38	IP
syndrome	O
patients	O
and	O
178	O
age	O
and	O
BMI	O
matched	O
controls	O
for	O
an	O
association	O
to	O
polycystic	BP
ovary-53	IP
syndrome	O
.	O

PS615	O
Many	O
reports	O
showed	O
that	O
even	O
though	O
the	O
causative	O
mutation	O
is	O
the	O
same	O
TGFBI	BG
R124H	IG
mutation-15	IG
,	O
there	O
are	O
severe	O
and	O
mild	O
phenotypes	O
of	O
the	O
corneal	BP
dystrophy-26	IP
.	O

PS635	O
We	O
did	O
not	O
observe	O
any	O
correlation	O
between	O
the	O
Ser326Cys	O
polymorphism	O
of	O
the	O
hOGG1	BG
gene-14	IG
and	O
endometrial	BP
cancer-17	IP
.	O

PS637	O
Deficiency	O
of	O
21	O
-	O
hydroxylase-5	BG
is	O
the	O
most	O
common	O
form	O
of	O
congenital	BP
adrenal	IP
hyperplasia-14	IP
.	O

PS672	O
Primary	O
hyperoxaluria-2	BP
type	O
1	O
is	O
caused	O
by	O
the	O
deficiency	O
of	O
the	O
liver	BG
enzyme	IG
alanine	IG
:	IG
glyoxylate	IG
aminotransferase-17	IG
which	O
results	O
in	O
increased	O
synthesis	O
and	O
excretion	O
of	O
oxalate	O
.	O

PS680	O
Since	O
a	O
strong	O
genotype	O
-	O
phenotype	O
correlation	O
exists	O
for	O
Multiple	O
endocrine	O
neoplasia-12	BP
type	O
2	O
,	O
the	O
detection	O
of	O
RET-19	BG
mutations	O
has	O
produced	O
a	O
major	O
impact	O
in	O
early	O
recognition	O
and	O
treatment	O
of	O
MTC	O
and	O
Multiple	O
endocrine	O
neoplasia-36	BP
type	O
2	O
.	O

PS691	O
Additional	O
genetic	O
factors	O
such	O
as	O
a	O
polymorphism	O
in	O
angiotensin	BG
-	IG
converting	IG
enzyme	IG
I	IG
gene-14	IG
may	O
also	O
contribute	O
to	O
a	O
high	O
incidence	O
of	O
sudden	BP
cardiac	IP
death-25	IP
in	O
Hypertrophic	O
cardiomyopathy	O
families	O
.	O

PS693	O
Signs	O
of	O
chronic	O
pancreatitis	O
(	O
ductal	O
changes	O
and	O
pancreatic	BP
calcifications-10	IP
)	O
,	O
pseudocysts-13	BP
,	O
common	BP
bile	IP
duct	IP
stenosis-18	IP
,	O
exocrine	O
or	O
endocrine	O
insufficiency	O
occurred	O
in	O
36	O
,	O
26	O
,	O
4	O
,	O
10	O
and	O
12	O
%	O
of	O
patients	O
with	O
CFTR	BG
gene-40	IG
mutations	O
respectively	O
,	O
which	O
was	O
not	O
different	O
from	O
patients	O
without	O
mutations	O
.	O

PS701	O
Cardio	O
-	O
facio	O
-	O
cutaneous	O
syndrome	O
is	O
a	O
sporadic	O
multiple	O
congenital	O
anomalies	O
/	O
mental	BP
retardation-15	IP
condition	O
principally	O
caused	O
by	O
mutations	O
in	O
BRAF-22	BG
,	O
MEK1-24	BG
,	O
and	O
MEK2-27	BG
.	O

PS706	O
Germline	BG
TP53-2	IG
mutations	O
result	O
in	O
cancer-6	BP
proneness	O
syndromes	O
known	O
as	O
Li	O
-	O
Fraumeni	O
,	O
Li	O
-	O
Fraumeni	O
-	O
like	O
,	O
and	O
nonsyndromic	O
predisposition	O
with	O
or	O
without	O
family	O
history	O
.	O

PS717	O
Mutations	O
in	O
the	O
Xeroderma	BG
pigmentosumD	IG
gene-6	IG
can	O
exhibit	O
three	O
distinct	O
clinical	O
phenotypes	O
:	O
Xeroderma-14	BP
pigmentosum	O
,	O
trichothiodystrophy	O
,	O
or	O
Xeroderma-20	BP
pigmentosum	O
combined	O
with	O
Cockayne	O
syndrome	O
.	O

PS719	O
The	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
site	O
of	O
mutation	O
of	O
the	O
Xeroderma	BG
pigmentosumD	IG
gene-17	IG
determines	O
the	O
clinical	O
phenotype	O
,	O
Xeroderma-23	BP
pigmentosum	O
or	O
trichothiodystrophy	O
.	O

PS738	O
The	O
apolipoprotein	BG
E4	IG
allele-4	IG
may	O
serve	O
as	O
an	O
independent	O
genetic	O
marker	O
predicting	O
severity	O
of	O
coronary	BP
artery	IP
disease-17	IP
.	O

PS747	O
Pyruvate	BG
kinase-2	IG
deficiency	O
is	O
a	O
rare	O
disease	O
but	O
an	O
important	O
cause	O
of	O
hereditary	O
nonspherocytic	O
hemolytic	BP
anemia-16	IP
.	O

PS770	O
The	O
two	O
major	O
subtypes	O
are	O
Glycogen	BP
storage	IP
disease-8	IP
type	O
Ia	O
(	O
MIM232200	O
)	O
,	O
caused	O
by	O
a	O
deficiency	O
of	O
glucose	BG
-	IG
6	IG
-	IG
phosphatase-24	IG
,	O
and	O
Glycogen	O
storage	O
disease	O
type	O
Ib	O
(	O
MIM232220	O
)	O
,	O
caused	O
by	O
a	O
deficiency	O
in	O
the	O
glucose	O
-	O
6	O
-	O
phosphate	O
transporter	O
.	O

PS772	O
Glycogen	O
storage	O
disease	O
type	O
Ib	O
patients	O
also	O
suffer	O
from	O
chronic	O
neutropenia-11	BP
and	O
functional	O
deficiencies	O
of	O
neutrophils	O
and	O
monocytes	O
,	O
which	O
is	O
treated	O
with	O
granulocyte	BG
colony	IG
stimulating	IG
factor-27	IG
to	O
restore	O
myeloid	O
function	O
.	O

PS773	O
The	O
diagnosis	O
of	O
Primary	O
hyperoxaluria-5	BP
type	O
1	O
is	O
complicated	O
by	O
heterogeneity	O
of	O
clinical	O
presentation	O
,	O
course	O
of	O
the	O
disease	O
,	O
biochemical	O
markers	O
,	O
alanine	O
:	O
glyoxylate	BG
aminotransferase-27	IG
enzymatic	O
activity	O
and	O
genotype	O
.	O

PS778	O
Choreoacanthocytosis-1	BP
is	O
a	O
slowly	O
progressive	O
multisystem	O
disorder	O
with	O
involuntary	O
movements	O
,	O
cognitive	BP
decline-13	IP
,	O
behavioral	O
changes	O
,	O
seizures-18	BP
,	O
and	O
polyneuropathy-21	BP
caused	O
by	O
mutations	O
in	O
the	O
VPS13A	BG
gene-28	IG
.	O

PS791	O
Circulating	O
and	O
platelet	BG
-	IG
activating	IG
factor-6	IG
-	O
primed	O
phagocyte	O
luminol	O
luminescence	O
responses	O
to	O
complement	O
-	O
opsonized	O
zymosan	O
were	O
increased	O
in	O
both	O
groups	O
of	O
infected	O
cystic	BP
fibrosis-26	IP
and	O
non	O
-	O
cystic	O
fibrosis	O
children	O
relative	O
to	O
uninfected	O
cystic	O
fibrosis	O
children	O
and	O
healthy	O
control	O
children	O
and	O
adults	O
.	O

PS797	O
The	O
human	BG
leucocyte	IG
antigen-4	IG
class	O
II	O
haplotype	O
DRB1	O
*	O
15	O
-	O
DQB1	O
*	O
06	O
is	O
associated	O
with	O
susceptibility	O
to	O
multiple	BP
sclerosis-21	IP
,	O
and	O
human	BG
leucocyte	IG
antigen-26	IG
class	O
I	O
associations	O
in	O
multiple	O
sclerosis	O
have	O
also	O
been	O
reported	O
.	O

PS801	O
The	O
region	O
includes	O
the	O
casein	BG
gene	IG
cluster-7	IG
and	O
several	O
candidate	O
genes	O
thought	O
to	O
influence	O
clinical	O
mastitis-16	BP
.	O

PS824	O
One	O
of	O
genes	O
in	O
the	O
region	O
,	O
GTF2I-8	BG
,	O
has	O
been	O
implicated	O
in	O
the	O
hypersociability	O
and	O
visuospatial	BP
deficits-18	IP
of	O
Williams	O
-	O
Beuren	O
syndrome	O
based	O
on	O
genotype	O
-	O
phenotype	O
correlation	O
studies	O
of	O
patients	O
with	O
atypical	O
deletions	O
.	O

PS832	O
We	O
conclude	O
that	O
although	O
hepatocyte	BG
growth	IG
factor-7	IG
signaling	O
is	O
critical	O
to	O
migration	O
,	O
invasion	O
,	O
and	O
apoptosis-17	BP
,	O
it	O
is	O
unlikely	O
that	O
hepatocyte	BG
growth	IG
factor	IG
genetic-26	IG
variation	O
plays	O
a	O
major	O
role	O
in	O
ovarian	BP
cancer-34	IP
mortality	O
.	O

PS838	O
Spinocerebellar	BP
ataxia-2	IP
type	O
2	O
is	O
caused	O
by	O
a	O
CAG	O
trinucleotide	O
repeat	O
expansion	O
within	O
the	O
coding	O
region	O
of	O
the	O
ataxin	BG
-	IG
2	IG
gene-22	IG
.	O

PS843	O
In	O
our	O
study	O
,	O
no	O
positive	O
correlations	O
between	O
cervical	O
cancer-10	BP
in	O
Frenchwomen	O
and	O
specific	O
HLA	BG
DR	IG
-	IG
DQ	IG
haplotypes-19	IG
has	O
been	O
found	O
.	O

PS850	O
In	O
four	O
large	O
pedigrees	O
with	O
heterozygous	O
familial	BP
hypercholesterolemia-8	IP
genetically	O
linked	O
to	O
the	O
low	BG
density	IG
lipoprotein	IG
receptor	IG
locus-17	IG
,	O
we	O
have	O
observed	O
a	O
strong	O
interaction	O
between	O
the	O
presence	O
of	O
familial	BP
hypercholesterolemia-30	IP
and	O
a	O
single	O
apolipoprotein	BG
E2	IG
allele-36	IG
,	O
resulting	O
in	O
a	O
markedly	O
increased	O
prevalence	O
of	O
type	O
III	O
dyslipoproteinemia-47	BP
.	O

PS858	O
There	O
was	O
no	O
correlation	O
between	O
the	O
occurrence	O
of	O
malignant	O
lymphoma-10	BP
of	O
the	O
thyroid	O
and	O
the	O
HLA	BG
antigens-17	IG
tested	O
,	O
but	O
patients	O
with	O
this	O
lymphoma	O
had	O
significantly	O
lower	O
frequency	O
of	O
the	O
Gm1	O
,	O
21	O
haplotype	O
than	O
healthy	O
persons	O
.	O

PS860	O
This	O
meta	O
-	O
analysis	O
suggests	O
that	O
it	O
is	O
unlikely	O
that	O
the	O
ERCC5	BG
Asp1104His-13	IG
polymorphism	O
may	O
contribute	O
to	O
individual	O
susceptibility	O
to	O
cancer-21	BP
risk	O
.	O

PS889	O
Neonatal	O
and	O
early	O
infantile	O
presentation	O
of	O
ARG1-7	BG
deficiency	O
with	O
severe	O
hyperammonemia-11	BP
remains	O
rare	O
and	O
only	O
six	O
such	O
cases	O
have	O
been	O
described	O
.	O

PS890	O
We	O
report	O
a	O
severely	O
affected	O
infant	O
with	O
ARG1-8	BG
deficiency	O
who	O
presented	O
at	O
6	O
weeks	O
of	O
age	O
with	O
lethargy	O
,	O
poor	O
feeding	O
and	O
severe	O
encephalopathy-24	BP
caused	O
by	O
hyperammonemia-27	BP
.	O

PS894	O
Primary	O
hyperoxaluria-2	BP
type	O
1	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
a	O
deficiency	O
of	O
alanine	BG
-	IG
glyoxylate	IG
aminotransferase-18	IG
,	O
which	O
is	O
encoded	O
by	O
a	O
single	O
copy	O
gene	O
(	O
AGXT	O
)	O
.	O

PS901	O
Mucopolysaccharidosis-1	BP
type	O
II	O
(	O
Mucopolysaccharidosis-5	BP
type	O
II	O
,	O
Hunter	O
syndrome	O
)	O
is	O
an	O
X	O
-	O
linked	O
lysosomal	O
storage	O
disease	O
caused	O
by	O
a	O
deficiency	O
of	O
iduronate	BG
-	IG
2	IG
-	IG
sulfatase-29	IG
.	O

PS922	O
The	O
tumor	BG
necrosis	IG
factor	IG
a-5	IG
,	O
b	O
,	O
c	O
,	O
d	O
,	O
and	O
e	O
microsatellites	O
were	O
determined	O
in	O
112	O
patients	O
with	O
rheumatoid	BP
arthritis-23	IP
and	O
99	O
healthy	O
controls	O
by	O
using	O
polymerase	O
chain	O
reaction	O
and	O
electrophoresis	O
with	O
sequencing	O
gel	O
.	O

PS956	O
A	O
missense	O
mutation	O
,	O
K124N	O
,	O
in	O
the	O
exon	O
9	O
of	O
the	O
TNNT2	BG
gene-14	IG
was	O
identified	O
in	O
a	O
41	O
-	O
year	O
-	O
old	O
female	O
patient	O
with	O
hypertrophic	BP
cardiomyopathy-28	IP
and	O
failed	O
to	O
be	O
detected	O
in	O
the	O
100	O
normal	O
controls	O
,	O
which	O
suggested	O
the	O
disease	O
-	O
causing	O
mutation	O
.	O

PS957	O
Mutation	O
in	O
tail	O
part	O
of	O
cardiac	BG
troponin	IG
T-8	IG
,	O
essential	O
for	O
it	O
'	O
s	O
binding	O
function	O
,	O
causes	O
the	O
disease	O
of	O
hypertrophic	BP
cardiomyopathy-23	IP
.	O

PS958	O
Xeroderma	BG
pigmentosum	IG
group	IG
G	IG
protein-5	IG
is	O
essential	O
for	O
the	O
nucleotide	O
excision	O
repair	O
system	O
,	O
and	O
genetic	O
variations	O
in	O
Xeroderma	BG
pigmentosum	IG
group	IG
G-22	IG
/	O
ERCC5-24	BG
that	O
affect	O
DNA	O
repair	O
capacity	O
may	O
contribute	O
to	O
the	O
risk	O
of	O
tobacco	O
-	O
induced	O
cancers-39	BP
,	O
including	O
squamous	BP
cell	IP
carcinoma-44	IP
of	O
the	O
head	O
and	O
neck	O
.	O

PS964	O
To	O
investigate	O
whether	O
or	O
not	O
CYP2C19	BG
genotype-7	IG
status	O
is	O
associated	O
with	O
cure	O
rate	O
for	O
Helicobacter	O
pylori	O
infection	O
in	O
patients	O
with	O
cirrhosis-21	BP
and	O
peptic	O
ulcer	O
,	O
achieved	O
with	O
2	O
weeks	O
of	O
triple	O
therapy	O
with	O
rabeprazole	O
,	O
amoxicillin	O
and	O
clarithromycin	O
.	O

PS966	O
Cleidocranial	BP
dysplasia-2	IP
is	O
an	O
autosomal	O
dominant	O
heritable	O
skeletal	O
disease	O
caused	O
by	O
heterozygous	O
mutations	O
in	O
the	O
osteoblast	BG
-	IG
specific	IG
transcription	IG
factor	IG
RUNX2-21	IG
.	O

PS979	O
Hypertrophic	BP
cardiomyopathy-2	IP
is	O
the	O
most	O
common	O
cause	O
of	O
sudden	BG
cardiac	IG
death-11	IG
in	O
the	O
young	O
and	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
elderly	O
.	O

PS986	O
Our	O
findings	O
suggest	O
that	O
crumbs	BG
homologue	IG
1	IG
mutations-8	IG
are	O
a	O
frequent	O
cause	O
of	O
Leber	O
congenital	O
amaurosis	O
and	O
are	O
strongly	O
associated	O
with	O
the	O
development	O
of	O
Coats	O
-	O
like	O
exudative	O
vasculopathy-29	BP
in	O
patients	O
with	O
retinitis	BP
pigmentosa-34	IP
.	O

PS990	O
Our	O
findings	O
suggest	O
that	O
crumbs	BG
homologue	IG
1	IG
mutations-8	IG
are	O
a	O
frequent	O
cause	O
of	O
Leber	O
congenital	O
amaurosis	O
and	O
are	O
strongly	O
associated	O
with	O
the	O
development	O
of	O
Coats	O
-	O
like	O
exudative	O
vasculopathy-29	BP
in	O
patients	O
with	O
retinitis	BP
pigmentosa-34	IP
.	O

PS1009	O
Up	O
to	O
date	O
,	O
14	O
patients	O
with	O
sporadic	O
non	O
-	O
autoimmune	BP
hyperthyroidism-12	IP
caused	O
by	O
sporadic	O
germline	O
mutations	O
in	O
the	O
TSH	BG
receptor-21	IG
gene	O
have	O
been	O
reported	O
.	O

PS1012	O
Six	O
autosomal	BP
dominant	IP
corneal	IP
dystrophies-5	IP
are	O
caused	O
by	O
mutations	O
in	O
the	O
TGFBI	BG
gene-16	IG
on	O
chromosome	O
5q31	O
:	O
three	O
types	O
of	O
lattice	O
corneal	BP
dystrophy-26	IP
,	O
including	O
type	O
I	O
and	O
type	O
IIIA	O
,	O
granular	O
,	O
Avellino	O
(	O
ACD	O
)	O
,	O
and	O
Reis	O
-	O
Bucklers	O
.	O

PS1021	O
Phenylketonuria-1	BP
is	O
a	O
classic	O
'	O
monogenic	O
'	O
autosomal	O
recessive	O
disease	O
in	O
which	O
mutation	O
at	O
the	O
human	BG
PAH	IG
locus-18	IG
was	O
deemed	O
sufficient	O
to	O
explain	O
the	O
impaired	O
function	O
of	O
the	O
enzyme	O
phenylalanine	BG
hydroxylase-31	IG
(	O
enzymic	O
phenotype	O
)	O
,	O
the	O
attendant	O
hyperphenylalaninemia	O
(	O
metabolic	O
phenotype	O
)	O
and	O
the	O
resultant	BP
mental	IP
retardation-48	IP
(	O
cognitive	BP
phenotype-51	IP
)	O
.	O

PS1038	O
Mucopolysaccharidosis-1	BP
type	O
I	O
is	O
an	O
autosomal	O
recessive	O
genetic	O
disorder	O
caused	O
by	O
deficiency	O
of	O
the	O
lysosomal	BG
glycosidase	IG
alpha	IG
-	IG
L	IG
-	IG
iduronidase-21	IG
.	O

PS1039	O
The	O
new	BG
CSNBX	IG
gene-4	IG
described	O
here	O
is	O
closely	O
linked	O
to	O
the	O
X	O
-	O
linked	O
retinitis	BG
pigmentosa	IG
type	IG
3	IG
gene	IG
region-20	IG
,	O
which	O
supports	O
the	O
hypothesis	O
that	O
there	O
may	O
be	O
a	O
functional	O
relationship	O
between	O
congenital	BP
stationary	IP
night	IP
blindness-37	IP
and	O
retinitis	BP
pigmentosa-40	IP
.	O

PS1043	O
While	O
expression	O
levels	O
showed	O
no	O
clear	O
association	O
with	O
chromosome9p21	O
genotype	O
,	O
association	O
of	O
high	O
p16-15	BG
(	O
INK4a-17	BG
)	O
and	O
low	BP
methylthioadenosine-21	IP
phosphorylase	O
expression	O
with	O
a	O
less	O
stable	O
plaque	O
phenotype	O
suggests	O
a	O
more	O
general	O
role	O
of	O
these	O
proteins	O
in	O
atherogenesis	O
.	O

PS1052	O
Both	O
R483W-2	BG
and	O
P459H-4	BG
mutations	O
are	O
confirmed	O
to	O
be	O
related	O
to	O
non	O
-	O
classical	O
congenital	BP
adrenal	IP
hyperplasia-17	IP
by	O
in	O
vitro	O
functional	O
study	O
,	O
with	O
phenotype	O
variance	O
of	O
R483W	O
in	O
Tunisian	O
and	O
Chinese	O
patients	O
.	O

PS1078	O
This	O
is	O
the	O
first	O
evidence	O
of	O
a	O
founder	O
effect	O
for	O
a	O
Pro370Leu	BG
myocilin	IG
mutation-14	IG
in	O
a	O
Chinese	O
primary	O
open	O
angle	O
glaucoma-21	BP
pedigree	O
.	O

PS1080	O
Reports	O
from	O
around	O
the	O
world	O
confirm	O
that	O
heterozygous	O
PAX6	BG
mutation-10	IG
is	O
the	O
major	O
cause	O
of	O
hereditary	O
aniridia	O
(	O
with	O
a	O
classic	O
phenotype	O
of	O
iris	BP
hypoplasia-25	IP
,	O
keratopathy	O
,	O
lens	O
opacity	O
,	O
and	O
foveal	BP
hypoplasia-34	IP
)	O
.	O

PS1095	O
Brachytelephalangia-1	BP
was	O
the	O
only	O
result	O
of	O
arylsulfatase	BG
E	IG
gene-9	IG
deletion	O
in	O
this	O
case	O
.	O

PS1108	O
Taken	O
together	O
,	O
the	O
low	O
penetrance	O
of	O
the	O
mutant	O
gene	O
,	O
the	O
lack	O
of	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
the	O
sex	O
-	O
dependent	O
effect	O
of	O
RET-26	BG
mutations	O
and	O
the	O
variable	O
clinical	O
expression	O
of	O
the	O
disease	O
support	O
the	O
existence	O
of	O
one	O
or	O
more	O
modifier	O
genes	O
in	O
familial	O
Hirschsprung	BP
disease-48	IP
.	O

PS1112	O
Screening	O
of	O
the	O
alpha	BG
-	IG
actin	IG
gene	IG
coding	IG
sequence-9	IG
may	O
account	O
for	O
the	O
identification	O
of	O
disease	O
-	O
causing	O
mutations	O
in	O
20	O
-	O
30	O
%	O
of	O
nemaline	O
myopathy-27	BP
patients	O
.	O

PS1113	O
Screening	O
of	O
the	O
alpha	BG
-	IG
actin	IG
gene	IG
coding	IG
sequence-9	IG
may	O
account	O
for	O
the	O
identification	O
of	O
disease	O
-	O
causing	O
mutations	O
in	O
20	O
-	O
30	O
%	O
of	O
nemaline	O
myopathy-27	BP
patients	O
.	O

PS1124	O
A	O
limited	O
study	O
of	O
23	O
spinal	BP
muscular	IP
atrophy-8	IP
families	O
also	O
failed	O
to	O
show	O
any	O
influence	O
of	O
apolipoprotein	BG
E	IG
genotype-19	IG
on	O
spinal	BP
muscular	IP
atrophy-23	IP
disease	O
severity	O
.	O

PS1130	O
The	O
association	O
of	O
IgA-4	BG
nephropathy-5	BP
and	O
other	O
polymorphism	O
sites	O
,	O
as	O
well	O
as	O
interaction	O
between	O
TFRC-16	BG
polymorphism	O
and	O
other	O
geneso	O
polymorphisms	O
,	O
neededs	O
to	O
be	O
further	O
investigated	O
.	O

PS1145	O
FOXL2-1	BG
has	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
cholesterol	O
homeostasis	O
,	O
steroid	O
metabolism	O
,	O
apoptosis-18	BP
,	O
reactive	O
oxygen	O
species	O
detoxification	O
and	O
inflammation	O
processes	O
.	O

PS1148	O
Cystic	BP
fibrosis-2	IP
is	O
characterized	O
by	O
defective	O
Cl	O
-	O
and	O
enhanced	O
Na	O
+	O
conductance	O
,	O
both	O
due	O
to	O
malfunction	O
of	O
the	O
cystic	BG
fibrosis	IG
transmembrane	IG
conductance	IG
regulator-25	IG
protein	O
in	O
airway	O
epithelial	O
cells	O
.	O

PS1154	O
Exon	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
,	O
single	O
-	O
stranded	O
conformational	O
polymorphism	O
,	O
and	O
sequencing	O
analysis	O
of	O
the	O
subject	O
'	O
s	O
androgen	BG
receptor	IG
gene-24	IG
were	O
performed	O
in	O
addition	O
to	O
hormone	O
-	O
binding	O
assays	O
in	O
skin	BP
fibroblasts-36	IP
from	O
the	O
patient	O
.	O

PS1155	O
Autosomal	O
-	O
recessive	O
Schimke	O
immuno	O
-	O
osseous	O
dysplasia	O
characterized	O
by	O
spondyloepiphyseal	O
dysplasia	O
,	O
focal	O
-	O
segmental	O
glomerulosclerosis	O
,	O
T	O
-	O
cell	O
immunodeficiency	O
and	O
facial	BP
dysmorphism-25	IP
is	O
caused	O
by	O
defects	O
in	O
the	O
SMARCAL1	BG
gene-33	IG
.	O

PS1156	O
Neurofibromatosis-1	BP
type	O
1	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
Neurofibromatosis	BG
type	IG
1	IG
gene-13	IG
which	O
consists	O
of	O
57	O
exons	O
and	O
encodes	O
a	O
GTPase	BG
activating	IG
protein-24	IG
,	O
neurofibromin-26	BG
.	O

PS1163	O
We	O
confirmed	O
in	O
a	O
large	O
cohort	O
of	O
ante	O
/	O
neonatal	O
Bartter	O
syndrome	O
that	O
deafness	O
,	O
transient	O
hyperkalaemia-17	BP
and	O
severe	O
hypokalaemic	BP
hypochloraemic	IP
alkalosis-22	IP
orientate	O
molecular	O
investigations	O
to	O
Bartter	O
syndromeND	O
,	O
KCNJ1-30	BG
and	O
CLCNKB	BG
genes-33	IG
,	O
respectively	O
.	O

PS1166	O
Thus	O
,	O
the	O
present	O
study	O
is	O
the	O
first	O
to	O
show	O
a	O
distinct	O
genotype	O
-	O
functional	O
phenotype	O
correlation	O
in	O
patients	O
with	O
Nemaline	O
myopathy-22	BP
due	O
to	O
a	O
nebulin-26	BG
mutation	O
,	O
and	O
provides	O
evidence	O
for	O
the	O
notion	O
that	O
dysregulated	O
thin	O
filament	O
length	O
contributes	O
to	O
muscle	BP
weakness-43	IP
in	O
Nemaline	O
myopathy-46	BP
patients	O
with	O
nebulin-49	BG
mutations	O
.	O

PS1167	O
Furthermore	O
,	O
a	O
striking	O
similarity	O
between	O
the	O
contractile	O
and	O
structural	O
phenotypes	O
of	O
nebulin-13	BG
-	O
deficient	O
mouse	O
muscle	O
and	O
human	O
Nemaline	O
myopathy	O
-	O
NEB	O
muscle	O
was	O
observed	O
,	O
indicating	O
that	O
the	O
nebulin-31	BG
knockout	O
model	O
is	O
well	O
suited	O
for	O
elucidating	O
the	O
functional	O
basis	O
of	O
muscle	BP
weakness-44	IP
in	O
Nemaline	O
myopathy-47	BP
and	O
for	O
the	O
development	O
of	O
treatment	O
strategies	O
.	O

PS1177	O
Hypomorphic	O
mutations	O
in	O
the	O
gene	BG
encoding	IG
nuclear	IG
factor	IG
kappaB	IG
essential	IG
modulator-11	IG
,	O
located	O
on	O
the	O
X	O
chromosome	O
,	O
impair	O
nuclear	BG
factor	IG
kappaB-22	IG
function	O
and	O
lead	O
to	O
ectodermal	BP
dysplasia-28	IP
with	O
immunodeficiency	O
with	O
increased	O
susceptibility	O
to	O
pyogenic	O
bacteria	O
,	O
viruses	O
and	O
nonpathogenic	O
mycobacterial	O
infections	O
.	O

PS1195	O
We	O
hypothesize	O
that	O
loss	O
of	O
imprinting	O
of	O
the	O
insulin	BG
-	IG
like	IG
growth	IG
factor	IG
II-14	IG
(	O
IGF2-16	BG
)	O
gene	O
is	O
associated	O
with	O
a	O
predisposition	O
to	O
sporadic	O
colorectal	BP
cancer-27	IP
.	O

PS1198	O
These	O
results	O
indicate	O
that	O
FGFR3-5	BG
and	O
PIK3CA-7	BG
mutations	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Stucco	O
keratosis	O
and	O
dermatosis	BP
papulosa	IP
nigra-20	IP
.	O

PS1199	O
CXCR1-1	BG
plays	O
a	O
key	O
role	O
in	O
mastitis	BP
resistance-8	IP
via	O
IL8-10	BG
signaling	O
pathway	O
,	O
with	O
the	O
CXCR1	BG
SNPs-17	IG
showing	O
a	O
different	O
degree	O
of	O
mastitis	BP
resistance-24	IP
.	O

PS1205	O
Recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
is	O
an	O
inherited	O
skin	BP
disease-9	IP
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	BG
VII	IG
collagen-19	IG
(	O
COL7A1-21	BG
)	O
.	O

PS1207	O
Mutations	O
in	O
Melanocortin	BG
4	IG
receptor-5	IG
result	O
in	O
a	O
distinct	O
obesity-10	BP
syndrome	O
that	O
is	O
inherited	O
in	O
a	O
codominant	O
manner	O
.	O

PS1212	O
This	O
review	O
describes	O
the	O
correlation	O
between	O
single	O
nucleotide	O
polymorphism	O
of	O
alpha	BG
-	IG
1	IG
antitrypsin-14	IG
,	O
alpha	BG
-	IG
1	IG
antichymotrypsin-19	IG
,	O
microsomal	BG
epoxide	IG
hydrolase	IG
-	IG
1-25	IG
,	O
matrix	BG
metalloproteinases	IG
-	IG
1-30	IG
,	O
-	O
9	O
,	O
-	O
12	O
,	O
glutathione	BG
S	IG
-	IG
transferases-41	IG
,	O
heme	BG
oxygenase	IG
-	IG
1-46	IG
,	O
tumor	BG
necrosis	IG
factor	IG
-	IG
alpha-52	IG
,	O
transforming	BG
growth	IG
factor	IG
-	IG
beta-58	IG
,	O
interleukins	BG
-	IG
1	IG
,	IG
-	IG
4	IG
,	IG
-	IG
13-68	IG
,	O
beta2	BG
-	IG
adrenergic	IG
receptor-73	IG
,	O
G	BG
-	IG
globulin-77	IG
genes	O
and	O
chronic	BP
obstructive	IP
pulmonary	IP
disease-83	IP
.	O

PS1214	O
Very	O
recently	O
,	O
mutations	O
in	O
the	O
cardiac	BG
ryanodine	IG
receptor	IG
gene-10	IG
have	O
been	O
identified	O
in	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia-18	BP
and	O
in	O
a	O
subgroup	O
of	O
patients	O
with	O
arrhythmogenic	BP
right	IP
ventricular	IP
cardiomyopathy-29	IP
.	O

PS1255	O
Autoantibodies	O
against	O
p53-3	BG
have	O
been	O
observed	O
in	O
many	O
cancers-9	BP
,	O
often	O
linked	O
with	O
abnormalities	O
in	O
the	O
TP53	BG
gene-18	IG
.	O

PS1272	O
An	O
increased	O
prevalence	O
of	O
both	O
hypertension-6	BP
and	O
cerebrovascular	O
stroke-9	BP
is	O
apparent	O
in	O
growth	BG
hormone-14	IG
deficiency	O
whilst	O
hypertension-17	BP
is	O
a	O
frequent	O
complication	O
in	O
acromegaly	O
.	O

PS1277	O
No	O
association	O
was	O
found	O
between	O
growth	BG
hormoneR-7	IG
genotype	O
and	O
either	O
hypertension-11	BP
or	O
stroke-13	BP
,	O
nor	O
was	O
any	O
interaction	O
noted	O
between	O
growth	BG
hormoneR-22	IG
and	O
growth	BG
hormone1-25	IG
genotypes	O
in	O
terms	O
of	O
a	O
disease	O
association	O
.	O

PS1287	O
Glycogen	BP
storage	IP
disease-3	IP
type	O
Ib	O
is	O
an	O
autosomal	O
recessive	O
inborn	O
error	O
of	O
metabolism	O
caused	O
by	O
deficiency	O
of	O
the	O
glucose	BG
-	IG
6	IG
-	IG
phosphate	IG
translocase-24	IG
.	O

PS1307	O
Elevated	O
IgD	BG
plasma-3	IG
levels	O
are	O
also	O
correlated	O
with	O
the	O
severity	O
of	O
Familial	O
Mediterranean	O
Fever	O
manifestations	O
,	O
and	O
especially	O
with	O
arthritis-20	BP
.	O

PS1345	O
The	O
frequency	O
of	O
12	O
different	O
mutations	O
of	O
the	O
steroid	BG
21	IG
-	IG
hydroxylase	IG
gene-13	IG
(	O
CYP21-15	BG
)	O
was	O
investigated	O
in	O
129	O
French	O
patients	O
affected	O
by	O
congenital	BP
adrenal	IP
hyperplasia-27	IP
due	O
to	O
steroid	BG
21	IG
-	IG
hydroxylase-33	IG
deficiency	O
.	O

PS1357	O
Specific	O
alleles	O
of	O
Ag1	BG
-	IG
CA-6	IG
and	O
C212-8	BG
showed	O
significant	O
association	O
with	O
spinal	BP
muscular	IP
atrophy-15	IP
,	O
particularly	O
in	O
type	O
I	O
spinal	BP
muscular	IP
atrophy-23	IP
.	O

PS1358	O
Hereditary	BP
tyrosinemia-2	IP
type	O
I	O
,	O
a	O
severe	O
disease	O
affecting	O
primarily	O
the	O
liver	O
,	O
is	O
caused	O
by	O
a	O
deficiency	O
of	O
fumarylacetoacetate	BG
hydrolase-21	IG
.	O

PS1371	O
Myotonic	BG
dystrophy	IG
type	IG
1-4	IG
(	O
DM1-6	BG
)	O
is	O
an	O
autosomal	O
-	O
dominant	O
muscular	BP
dystrophy-14	IP
caused	O
by	O
expansion	O
of	O
cytosine	O
-	O
thymine	O
-	O
guanine	O
trinucleotide	O
repeats	O
in	O
the	O
myotonic	BG
dystrophy	IG
protein	IG
kinase-31	IG
(	O
DMPK-33	BG
)	O
gene	O
.	O

PS1372	O
Tetrahydrobiopterin	O
(	O
BH4	O
)	O
responsiveness	O
in	O
patients	O
with	O
mutations	O
in	O
the	O
phenylalanine	BG
hydroxylase-13	IG
gene	O
is	O
a	O
recently	O
recognized	O
subtype	O
of	O
hyperphenylalaninemia-21	BP
characterized	O
by	O
a	O
positive	O
BH4	O
loading	O
test	O
.	O

PS1385	O
In	O
summary	O
,	O
we	O
conclude	O
that	O
the	O
dinucleotide	O
CA	O
polymorphism	O
in	O
the	O
Calcitonin-13	BG
gene	O
may	O
become	O
a	O
useful	O
marker	O
for	O
genetic	O
studies	O
of	O
Osteoarthritis-24	BP
of	O
the	O
knee	O
in	O
Mexican	O
population	O
.	O

PS1386	O
Mutations	O
in	O
the	O
L1	BG
gene-5	IG
are	O
responsible	O
for	O
four	O
X	O
linked	O
neurological	O
conditions	O
:	O
X	O
linked	O
hydrocephalus-17	BP
(	O
HSAS	O
)	O
,	O
MASA	O
syndrome	O
,	O
complicated	O
spastic	BP
paraplegia-27	IP
type	O
1	O
,	O
and	O
X	O
linked	O
agenesis	BP
of	IP
the	IP
corpus	IP
callosum-38	IP
.	O

PS1387	O
As	O
the	O
clinical	O
picture	O
of	O
these	O
four	O
L1-8	BG
associated	O
diseases	O
shows	O
considerable	O
overlap	O
and	O
is	O
characterised	O
by	O
Corpus	BP
callosum	IP
hypoplasia-20	IP
,	O
mental	BP
Retardation-23	IP
,	O
Adducted	BP
thumbs-26	IP
,	O
Spastic	BP
paraplegia-29	IP
,	O
and	O
Hydrocephalus-32	BP
,	O
these	O
conditions	O
have	O
recently	O
been	O
lumped	O
together	O
into	O
the	O
CRASH-43	BG
syndrome	O
.	O

PS1404	O
Cystic	BP
fibrosis-2	IP
is	O
caused	O
by	O
mutations	O
in	O
the	O
Cystic	BG
fibrosis	IG
transmembrane	IG
conductance	IG
regulator-13	IG
gene	O
which	O
encodes	O
a	O
protein	O
expressed	O
in	O
the	O
apical	O
membrane	O
of	O
exocrine	O
epithelial	O
cells	O
.	O

PS1420	O
We	O
report	O
51	O
patients	O
with	O
Merosin-6	BG
deficient	O
congenital	O
muscular	BP
dystrophy-10	IP
1A	O
and	O
examine	O
the	O
relationship	O
between	O
degree	O
of	O
merosin-19	BG
expression	O
,	O
genotype	O
and	O
clinical	O
features	O
.	O

PS1421	O
This	O
large	O
study	O
identified	O
novel	O
LAMA2	BG
mutations-7	IG
and	O
highlights	O
the	O
role	O
of	O
immunohistochemical	O
studies	O
for	O
merosin	O
status	O
in	O
predicting	O
clinical	O
severity	O
of	O
Merosin-23	BG
deficient	O
congenital	O
muscular	BP
dystrophy-27	IP
1A	O
.	O

PS1440	O
CACNA1A-1	BG
is	O
responsible	O
for	O
both	O
episodic	O
ataxia-7	BP
type	O
2	O
and	O
spinocerebellar	BP
ataxia-12	IP
type	O
6	O
.	O

PS1453	O
Mucopolysaccharidosis-1	BP
type	O
I	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
resulting	O
from	O
a	O
deficiency	O
of	O
the	O
lysosomal	BG
glycosidase-16	IG
,	O
alpha	BG
-	IG
L	IG
-	IG
iduronidase-22	IG
.	O

PS1476	O
These	O
results	O
demonstrate	O
that	O
,	O
in	O
the	O
correct	O
genetic	O
background	O
,	O
WDR36	BG
sequence	IG
variants-14	IG
can	O
lead	O
to	O
an	O
altered	O
cellular	O
phenotype	O
,	O
supporting	O
the	O
theory	O
that	O
WDR36	O
participates	O
in	O
polygenic	O
forms	O
of	O
glaucoma-33	BP
.	O

PS1480	O
Accordingly	O
,	O
we	O
propose	O
that	O
our	O
patient	O
'	O
s	O
ophthalmologic	BP
abnormalities-11	IP
result	O
from	O
haploinsufficiency	O
of	O
the	O
transcription	O
factor	O
FOXC1-19	BG
.	O

PS1498	O
In	O
a	O
large	O
number	O
of	O
studies	O
,	O
members	O
of	O
the	O
microRNA	BG
-	IG
34	IG
family-14	IG
such	O
as	O
microRNA	BG
-	IG
34a-19	IG
,	O
microRNA	BG
-	IG
34b-23	IG
,	O
microRNA	BG
-	IG
34c-27	IG
,	O
as	O
well	O
as	O
microRNA	O
-	O
125b	O
and	O
microRNA	O
-	O
155	O
,	O
have	O
been	O
shown	O
to	O
be	O
regulators	O
of	O
apoptosis-47	BP
.	O

PS1503	O
Cleidocranial	BP
dysplasia-2	IP
is	O
caused	O
by	O
mutations	O
in	O
the	O
transcription	O
factor	O
RUNX2-11	BG
,	O
which	O
is	O
known	O
to	O
function	O
as	O
a	O
major	O
regulator	O
of	O
bone	O
differentiation	O
.	O

PS1512	O
Our	O
studies	O
have	O
shown	O
no	O
TIGR	BG
gene-7	IG
changes	O
that	O
can	O
be	O
recognized	O
as	O
causative	O
mutations	O
in	O
development	O
of	O
primary	O
open	O
angle	O
glaucoma-22	BP
.	O

PS1515	O
This	O
heterogeneity	O
in	O
beta	BG
-	IG
glucuronidase	IG
gene-7	IG
mutations	O
contributes	O
to	O
the	O
extensive	O
clinical	O
variability	O
among	O
patients	O
with	O
Mucopolysaccharidosis-18	BP
VII	O
.	O

PS1517	O
The	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
Chinese	O
children	O
with	O
novel	O
merosin-11	BG
-	O
deficient	O
congenital	O
muscular	BP
dystrophy-16	IP
is	O
reported	O
.	O

PS1546	O
We	O
have	O
demonstrated	O
previously	O
,	O
that	O
overexpression	O
of	O
the	O
human	BG
laminin	IG
alpha2-12	IG
in	O
skeletal	O
muscle	O
in	O
dy	O
(	O
2J	O
)	O
/	O
dy	O
(	O
2J	O
)	O
and	O
dy	O
(	O
W	O
)	O
/	O
dy	O
(	O
W	O
)	O
mice	O
under	O
the	O
control	O
of	O
a	O
striated	O
muscle	O
-	O
specific	O
creatine	BG
kinase	IG
promoter-48	IG
substantially	O
prevented	O
the	O
muscular	BP
dystrophy-53	IP
in	O
these	O
mice	O
.	O

PS1550	O
Mutations	O
in	O
ATP7A-3	BG
or	O
ATP7B-5	BG
disrupt	O
the	O
homeostatic	O
copper	O
balance	O
,	O
resulting	O
in	O
copper	BP
deficiency-15	IP
(	O
Menkes	O
disease	O
)	O
or	O
copper	O
overload	O
(	O
Wilson	O
disease	O
)	O
,	O
respectively	O
.	O

PS1571	O
To	O
determine	O
the	O
mutational	O
spectrum	O
in	O
the	O
Tunisian	O
Congenital	BP
adrenal	IP
hyperplasia-11	IP
population	O
,	O
the	O
CYP21-15	BG
active	O
gene	O
was	O
analyzed	O
in	O
51	O
unrelated	O
patients	O
using	O
our	O
cascade	O
strategy	O
(	O
digestion	O
by	O
restriction	O
enzyme	O
,	O
sequencing	O
)	O
.	O

PS1578	O
Distinct	O
dominant	O
activating	O
mutations	O
in	O
the	O
RET	BG
proto	IG
-	IG
oncogene-10	IG
are	O
responsible	O
for	O
the	O
development	O
of	O
multiple	O
endocrine	O
neoplasia-19	BP
type	O
2	O
.	O

PS1584	O
A	O
statistically	O
significant	O
correlation	O
for	O
>	O
or	O
=	O
4	O
SMN2	O
copies	O
with	O
Spinal	BP
muscular	IP
atrophy-15	IP
type	O
IIIb	O
or	O
a	O
milder	O
phenotype	O
suggests	O
that	O
SMN2-24	BG
copy	O
number	O
can	O
be	O
used	O
as	O
a	O
clinical	O
prognostic	O
indicator	O
in	O
Spinal	BP
muscular	IP
atrophy-38	IP
patients	O
.	O

PS1594	O
The	O
Gln368stop	BG
mutation-3	IG
has	O
recently	O
been	O
found	O
in	O
several	O
cases	O
of	O
late	O
-	O
onset	O
primary	O
open	O
-	O
angle	O
glaucoma-19	BP
.	O

PS1628	O
Juvenile	BP
polyposis-2	IP
and	O
hereditary	O
hemorrhagic	BP
telangiectasia-6	IP
are	O
clinically	O
distinct	O
diseases	O
caused	O
by	O
mutations	O
in	O
SMAD4-15	BG
and	O
BMPR1A-17	BG
(	O
for	O
Juvenile	O
polyposis	O
)	O
and	O
endoglin-24	BG
and	O
ALK1-26	BG
(	O
for	O
hemorrhagic	BP
telangiectasia-30	IP
)	O
.	O

PS1641	O
Coffin	O
-	O
Lowry	O
syndrome	O
is	O
an	O
X	O
-	O
linked	O
mental	BP
retardation-11	IP
syndrome	O
caused	O
by	O
defects	O
in	O
the	O
RSK2	BG
gene-19	IG
.	O

PS1646	O
We	O
examined	O
the	O
prevalence	O
,	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
and	O
natural	O
history	O
of	O
lamin	BG
A	IG
/	IG
C	IG
gene-19	IG
mutations	O
in	O
subjects	O
with	O
dilated	BP
cardiomyopathy-25	IP
.	O

PS1658	O
Deficiency	O
of	O
21	O
-	O
hydroxylase-5	BG
is	O
the	O
most	O
common	O
form	O
of	O
congenital	BP
adrenal	IP
hyperplasia-14	IP
(	O
CAH	O
-	O
21OH	O
)	O
.	O

PS1665	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
implication	O
of	O
copy	O
number	O
changes	O
of	O
epidermal	BG
growth	IG
factor	IG
receptor-19	IG
in	O
lung	O
cancer-22	BP
pathogenesis	O
.	O

PS1680	O
These	O
results	O
provide	O
further	O
evidence	O
for	O
the	O
phenotypic	O
differences	O
of	O
genetically	O
defined	O
Spinocerebellar	BG
ataxias	IG
type	IG
1-16	IG
and	O
SCA2-18	BG
patients	O
,	O
expressed	O
by	O
more	O
frequent	O
involvement	O
of	O
the	O
pyramidal	O
tract	O
and	O
depression-31	BP
reaction	O
in	O
Spinocerebellar	O
ataxias-35	BP
type	O
1	O
,	O
in	O
contrast	O
to	O
peripheral	O
nerve	O
involvement	O
and	O
extrapyramidal	O
signs	O
in	O
the	O
clinical	O
feature	O
of	O
SCA2-53	BG
phenotype	O
.	O

PS1682	O
Findings	O
suggest	O
that	O
the	O
monoamine	BG
oxidase	IG
A	IG
untranslated	IG
region	IG
variable	IG
number	IG
of	IG
tandem	IG
repeats	IG
genotype-15	IG
,	O
prenatal	O
exposure	O
to	O
cigarettes	O
and	O
sex	O
interact	O
to	O
predict	O
antisocial	BP
behavior-27	IP
and	O
related	O
information	O
-	O
processing	O
patterns	O
.	O

PS1696	O
The	O
results	O
obtained	O
from	O
this	O
cross	O
-	O
sectional	O
/	O
longitudinal	O
study	O
support	O
the	O
hypothesis	O
that	O
the	O
vascular	O
dysfunction	O
characteristic	O
of	O
systemic	BP
lupus	IP
erythematosus-23	IP
may	O
be	O
related	O
to	O
a	O
dramatically	O
altered	O
distribution	O
of	O
endothelial	BG
protein	IG
C	IG
receptor-36	IG
,	O
both	O
soluble	O
and	O
membrane	O
-	O
bound	O
forms	O
.	O

PS1697	O
Epidermolysis	O
bullosa	O
simplex	O
is	O
a	O
group	O
of	O
autosomal	O
dominant	O
genetic	O
skin	BP
disorders-12	IP
caused	O
by	O
mutations	O
of	O
the	O
keratin	O
genes	O
KRT5-20	BG
and	O
KRT14-22	BG
.	O

PS1703	O
During	O
the	O
last	O
few	O
years	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
some	O
syndromic	O
craniosynostosis-14	BP
and	O
short	O
-	O
limb	O
dwarfism	O
syndromes	O
,	O
a	O
heterogeneous	O
group	O
comprising	O
of	O
11	O
distinct	O
clinical	O
entities	O
,	O
are	O
caused	O
by	O
mutations	O
in	O
one	O
of	O
three	O
fibroblast	BG
growth	IG
factor	IG
receptor	IG
genes-44	IG
(	O
FGFR1-46	BG
,	O
FGFR2-48	BG
,	O
and	O
FGFR3-51	BG
)	O
.	O

PS1707	O
To	O
study	O
whether	O
genetic	O
variants	O
of	O
macrophage	BG
migration	IG
inhibitory	IG
factor-10	IG
,	O
the	O
migration	O
inhibitory	O
factor	O
-	O
173G	O
>	O
C	O
and	O
CATT	O
(	O
5	O
-	O
8	O
)	O
alleles	O
,	O
are	O
associated	O
with	O
disease	O
severity	O
and	O
levels	O
of	O
circulating	O
migration	O
inhibitory	O
factor	O
in	O
patients	O
with	O
rheumatoid	BP
arthritis-45	IP
.	O

PS1709	O
Multiple	O
endocrine	O
neoplasia-3	BP
type	O
2	O
is	O
an	O
autosomal	O
dominant	O
tumour	O
syndrome	O
caused	O
by	O
germline	O
activating	O
mutations	O
of	O
the	O
RET	BG
proto	IG
-	IG
oncogene-22	IG
.	O

PS1714	O
Mucopolysaccharidosis-1	BP
type	O
IIID	O
,	O
or	O
Sanfilippo	O
syndrome	O
type	O
D	O
,	O
is	O
a	O
rare	O
autosomal	O
recessive	O
lysosomal	O
storage	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
N	BG
-	IG
acetylglucosamine	IG
-	IG
6	IG
-	IG
sulfatase-30	IG
(	O
GNS-32	BG
)	O
gene	O
,	O
leading	O
to	O
impaired	O
degradation	O
of	O
heparan	O
sulfate	O
.	O

PS1715	O
To	O
elucidate	O
the	O
association	O
between	O
the	O
genotype	O
of	O
human	BG
leukocyte	IG
antigen	IG
class	IG
II	IG
genes-14	IG
and	O
the	O
clinical	O
phenotype	O
of	O
Gastric	BP
cancer-21	IP
,	O
polymorphisms	O
of	O
human	BG
leukocyte	IG
antigen-27	IG
-	O
DRB1-29	BG
and	O
human	BG
leukocyte	IG
antigen	IG
-	IG
DQB1-35	IG
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
with	O
sequence	O
-	O
specific	O
primers	O
in	O
106	O
Taiwanese	O
patients	O
with	O
Gastric	BP
cancer-53	IP
and	O
in	O
208	O
healthy	O
controls	O
.	O

PS1720	O
The	O
gene	O
involved	O
in	O
familial	O
hypertrophic	BP
cardiomyopathy-7	IP
on	O
chromosome	O
11	O
was	O
recently	O
identified	O
as	O
the	O
cardiac	BG
myosin	IG
binding	IG
protein	IG
-	IG
C-21	IG
gene	O
.	O

PS1721	O
In	O
adults	O
(	O
n	O
=	O
33	O
)	O
bearing	O
a	O
splice	O
acceptor	O
site	O
mutation	O
in	O
the	O
myosin	BG
binding	IG
protein	IG
-	IG
C	IG
gene-21	IG
,	O
penetrance	O
of	O
familial	O
hypertrophic	BP
cardiomyopathy-27	IP
was	O
incomplete	O
(	O
69	O
%	O
)	O
and	O
ventricular	BP
hypertrophy-36	IP
mild	O
.	O

PS1728	O
RET	O
mutations	O
in	O
HSCR1-4	BG
have	O
been	O
shown	O
to	O
cause	O
a	O
loss	O
of	O
RET-13	BG
function	O
,	O
while	O
the	O
cancer-18	BP
syndromes	O
result	O
in	O
RET-22	BG
oncogenic	O
activation	O
.	O

PS1739	O
Clinical	O
Relevance	O
We	O
demonstrate	O
that	O
phenotypic	O
variation	O
of	O
nystagmus-9	BP
occurs	O
in	O
families	O
with	O
FRMD7-14	BG
mutations	O
.	O

PS1742	O
With	O
the	O
discovery	O
of	O
MYH-5	BG
associated	O
polyposis-7	BP
syndrome	O
,	O
the	O
clinical	O
differences	O
have	O
become	O
unclear	O
.	O

PS1750	O
Comparison	O
between	O
the	O
SCA	O
groups	O
showed	O
that	O
cerebellar	O
and	O
brainstem	BP
atrophy-11	IP
was	O
more	O
severe	O
in	O
SCA2-16	BG
than	O
in	O
SCA1-19	BG
and	O
SCA3-21	BG
.	O

PS1771	O
Uroporphyrinogen	BG
III	IG
synthase-3	IG
genotypes	O
associated	O
with	O
poor	O
prognosis	O
would	O
additionally	O
justify	O
consideration	O
for	O
a	O
bone	BP
marrow	IP
transplantation-17	IP
.	O

PS1786	O
:	O
Pseudoxanthoma-2	BP
elasticum	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
of	O
elastic	O
tissue	O
in	O
the	O
skin	O
,	O
eyes	O
,	O
and	O
cardiovascular	O
system	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
ABCC6	BG
gene-28	IG
.	O

PS1797	O
Association	O
with	O
TNFSF15-3	BG
and	O
pediatric	O
ulcerative	O
colitis-7	BP
was	O
also	O
reported	O
.	O

PS1806	O
Two	O
polymorphisms	O
(	O
C3435T	O
and	O
G2677T	O
/	O
A	O
)	O
of	O
the	O
multidrug	BG
resistance	IG
1	IG
gene-15	IG
have	O
been	O
correlated	O
with	O
the	O
altered	O
P	BG
-	IG
glycoprotein-24	IG
expression	O
and	O
function	O
in	O
humans	O
,	O
and	O
associated	O
with	O
predisposition	O
to	O
ulcerative	BP
colitis-37	IP
and	O
Crohn	O
'	O
s	O
disease	O
.	O

PS1826	O
Familial	O
Mediterranean	O
fever-3	BP
is	O
an	O
autosomal	O
-	O
recessive	O
inherited	O
inflammatory	O
disease	O
caused	O
by	O
mutations	O
in	O
the	O
MEFV	O
gene	O
that	O
encodes	O
pyrin	BG
/	IG
marenostrin-23	IG
.	O

PS1834	O
To	O
determine	O
the	O
molecular	O
basis	O
of	O
phenylketonuria-7	BP
and	O
related	O
hyperphenylalaninemia-10	BP
and	O
to	O
establish	O
correlations	O
between	O
phenylalanine	BG
hydroxylase-17	IG
genotypes	O
and	O
biochemical	O
and	O
clinical	O
phenotypes	O
in	O
an	O
ethnically	O
diverse	O
US	O
population	O
,	O
phenylalanine	BG
hydroxylase-32	IG
genotypes	O
were	O
determined	O
in	O
35	O
patients	O
with	O
phenylketonuria	O
or	O
hyperphenylalaninemia-42	BP
and	O
1	O
carrier	O
from	O
the	O
Medical	O
Genetics	O
Clinic	O
of	O
the	O
Emory	O
University	O
School	O
of	O
Medicine	O
.	O

PS1839	O
BReast	BG
Cancer	IG
susceptibility	IG
gene	IG
2-5	IG
germline	O
mutation	O
carriers	O
are	O
at	O
increased	O
risk	O
for	O
breast	O
and	O
ovarian	O
cancers-17	BP
.	O

PS1847	O
It	O
is	O
speculated	O
that	O
less	O
severe	O
mutations	O
in	O
this	O
channel	O
could	O
result	O
in	O
a	O
less	O
severe	O
form	O
of	O
hypertension-19	BP
which	O
may	O
correspond	O
to	O
patients	O
suffering	O
from	O
high	O
blood	O
pressure	O
with	O
low	O
plasma	BG
renin-33	IG
activity	O
.	O

PS1848	O
In	O
the	O
last	O
few	O
years	O
the	O
knowledge	O
of	O
the	O
characteristics	O
of	O
alanine	O
:	O
glyoxylate	BG
aminotransferase-15	IG
and	O
the	O
transfer	O
of	O
this	O
information	O
into	O
some	O
pathogenic	O
variants	O
have	O
significantly	O
contributed	O
to	O
the	O
improvement	O
of	O
the	O
understanding	O
at	O
the	O
molecular	O
level	O
of	O
the	O
Primary	O
Hyperoxaluria-42	BP
Type	O
1	O
pathogenesis	O
.	O

PS1859	O
Our	O
objective	O
was	O
(	O
i	O
)	O
to	O
determine	O
whether	O
hyperprolinemia	O
is	O
associated	O
with	O
increased	O
susceptibility	O
for	O
any	O
of	O
three	O
psychiatric	O
conditions	O
(	O
schizophrenia-23	BP
,	O
schizoaffective	BP
disorder-26	IP
and	O
bipolar	BP
disorder-29	IP
)	O
and	O
(	O
ii	O
)	O
to	O
establish	O
a	O
correlation	O
between	O
hyperprolinemia-40	BP
and	O
proline	BG
dehydrogenase-43	IG
genotypes	O
.	O

PS1870	O
Clinical	O
,	O
familial	O
,	O
and	O
,	O
more	O
recently	O
,	O
genetic	O
linkage	O
studies	O
suggest	O
that	O
overlapping	O
genetic	BG
susceptibility-17	IG
might	O
contribute	O
to	O
both	O
schizophrenia-22	BP
and	O
bipolar	BP
disorder-25	IP
.	O

PS1871	O
Neurofibromatosis-1	BP
type	O
1	O
,	O
an	O
autosomal	O
dominantly	O
-	O
inherited	O
disorder	O
,	O
is	O
mainly	O
characterized	O
by	O
the	O
occurrence	O
of	O
multiple	O
dermal	O
neurofibromas	O
and	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
Neurofibromatosis	BG
type	IG
1	IG
gene-32	IG
,	O
a	O
tumor	O
suppressor	O
gene	O
.	O

PS1879	O
Our	O
data	O
suggest	O
that	O
hemizygous	O
loss	O
of	O
NUFIP1-8	BG
and	O
PCDH8-10	BG
may	O
contribute	O
to	O
psychomotor	BP
delay-15	IP
,	O
deletion	O
of	O
MTLR1-19	BG
to	O
microcephaly-21	BP
and	O
loss	O
of	O
EDNRB	O
to	O
feeding	O
difficulties	O
and	O
deafness	O
.	O

PS1880	O
We	O
examined	O
whether	O
the	O
degree	O
of	O
residual	O
activity	O
from	O
the	O
mutant	O
phenylalanine	BG
hydroxylase-13	IG
allele	O
affected	O
phenylalanine	O
metabolism	O
in	O
heterozygotes	O
for	O
phenylketonuria-21	BP
or	O
non	O
-	O
phenylketonuria	O
hyperphenylalaninaemia-26	BP
.	O

PS1888	O
Propionic	BP
acidaemia-2	IP
is	O
an	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
mutations	O
in	O
either	O
of	O
the	O
propionyl	BG
-	IG
CoA	IG
carboxylaseA	IG
or	IG
propionyl	IG
-	IG
CoA	IG
carboxylaseB	IG
genes-24	IG
which	O
encode	O
the	O
alpha	O
and	O
beta	O
subunits	O
,	O
respectively	O
,	O
of	O
the	O
mitochondrial	O
enzyme	O
propionyl	O
-	O
CoA	O
carboxylase	O
.	O

PS1907	O
Somatic	BG
PTEN-2	IG
deletions	O
and	O
mutations	O
were	O
observed	O
in	O
sporadic	O
breast	O
,	O
brain	O
,	O
prostate	O
and	O
kidney	O
cancer-17	BP
cell	O
lines	O
and	O
in	O
several	O
primary	O
tumours	O
such	O
as	O
endometrial	O
carcinomas	O
,	O
malignant	BP
melanoma-31	IP
and	O
thyroid	O
tumours	O
.	O

PS1911	O
Cytokine	O
-	O
mediated	O
downregulation	O
of	O
the	O
major	O
human	O
efflux	O
transporter	O
ABCB1	O
in	O
inflamed	O
intestine	O
of	O
ulcerative	O
colitis-17	BP
patients	O
is	O
presumably	O
dependent	O
on	O
disease	O
activity	O
,	O
with	O
a	O
possible	O
contribution	O
from	O
IL8-31	BG
.	O

PS1930	O
TSH	BG
receptor-2	IG
germline	O
mutations	O
occur	O
as	O
activating	O
mutations	O
in	O
familial	O
non	O
-	O
autoimmune	BP
hyperthyroidism-14	IP
or	O
sporadic	O
non	O
-	O
autoimmune	BP
hyperthyroidism-20	IP
.	O

PS1933	O
However	O
,	O
additional	O
genetic	O
,	O
constitutional	O
or	O
environmental	O
factors	O
are	O
most	O
likely	O
responsible	O
for	O
the	O
phenotypic	O
variations	O
of	O
the	O
disease	O
and	O
the	O
lack	O
of	O
correlation	O
between	O
in	O
vitro	O
activities	O
of	O
the	O
TSH	BG
receptor-33	IG
mutations	O
and	O
the	O
severity	O
of	O
hyperthyroidism-39	BP
.	O

PS1945	O
Mucopolysaccharidosis-1	BP
type	O
II	O
is	O
X	O
-	O
linked	O
recessive	O
lysosomal	O
storage	O
disorder	O
resulting	O
from	O
the	O
defective	O
activity	O
of	O
the	O
enzyme	BG
iduronate	IG
-	IG
2	IG
-	IG
sulfatase-24	IG
.	O

PS1949	O
Congenital	BP
adrenal	IP
hyperplasia-3	IP
comprises	O
autosomal	O
recessive	O
disorders	O
mainly	O
due	O
to	O
defects	O
in	O
the	O
21	BG
-	IG
hydroxylase-16	IG
(	O
CYP21-18	BG
)	O
gene	O
.	O

PS1954	O
A	O
population	O
genetic	O
survey	O
revealed	O
that	O
the	O
retinal	O
degeneration	O
in	O
the	O
Abyssinian	BG
cat	IG
allele-14	IG
is	O
in	O
moderate	O
abundance	O
in	O
the	O
Abyssinian	O
breed	O
in	O
Europe	O
and	O
Australia-26	BP
.	O

PS1960	O
To	O
date	O
,	O
only	O
eight	O
mutations	O
have	O
been	O
described	O
in	O
the	O
atlastin	BG
gene-13	IG
,	O
which	O
was	O
reported	O
to	O
account	O
for	O
about	O
10	O
%	O
of	O
all	O
AD	O
-	O
Hereditary	O
spastic	BP
paraplegia-30	IP
families	O
.	O

PS1961	O
However	O
,	O
it	O
confirmed	O
the	O
early	O
onset	O
of	O
this	O
form	O
of	O
Hereditary	O
spastic	BP
paraplegia-14	IP
,	O
which	O
was	O
observed	O
in	O
almost	O
all	O
affected	O
individuals	O
with	O
a	O
mutation	O
in	O
the	O
atlastin	BG
gene-30	IG
.	O

PS1967	O
Val606Met	O
mutation	O
was	O
identified	O
in	O
exon	O
16	O
in	O
one	O
family	O
and	O
Val606Met-12	BG
mutation	O
was	O
identified	O
in	O
4	O
out	O
of	O
8	O
family	O
members	O
in	O
this	O
pedigree	O
and	O
3	O
out	O
of	O
4	O
Val606Met	O
carriers	O
suffered	O
from	O
hypertrophic	BP
cardiomyopathy-36	IP
.	O

PS1968	O
The	O
Val606Met	BG
mutation-3	IG
located	O
at	O
the	O
actin-7	BG
-	O
binding	O
region	O
of	O
the	O
cardiac	BG
beta-14	IG
myosin	BG
heavy	IG
chain	IG
gene	IG
gene-19	IG
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
hypertrophic	BP
cardiomyopathy-27	IP
in	O
this	O
Chinese	O
pedigree	O
.	O

PS1971	O
However	O
,	O
there	O
was	O
no	O
association	O
between	O
the	O
genotypes	O
of	O
the	O
matrix	BG
metalloproteinase	IG
-	IG
2-15	IG
,	O
vascular	BG
endothelial	IG
growth	IG
factor-20	IG
and	O
HIF1A-22	BG
single	O
nucleotide	O
polymorphisms	O
and	O
clinicopathological	O
parameters	O
of	O
colorectal	BP
cancer-31	IP
.	O

PS1988	O
X	O
-	O
linked	O
(	O
Bruton	O
'	O
s	O
)	O
agammaglobulinemia-9	BP
(	O
XLA	O
)	O
is	O
a	O
rare	O
immunodeficiency	O
caused	O
by	O
a	O
block	O
in	O
B	O
-	O
cell	O
development	O
caused	O
by	O
mutations	O
in	O
the	O
Bruton	BG
'	IG
s	IG
tyrosine	IG
kinase-35	IG
gene	O
.	O

PS2001	O
We	O
also	O
found	O
that	O
T235	BG
allele-6	IG
frequencies	O
decreased	O
with	O
age	O
,	O
indicating	O
that	O
in	O
the	O
Emirati	O
population	O
,	O
T235	BG
alleles-20	IG
are	O
associated	O
with	O
a	O
reduced	O
life	O
span	O
and	O
that	O
this	O
effect	O
could	O
occur	O
through	O
independent	O
mechanisms	O
underlying	O
genetic	O
susceptibilities	O
to	O
both	O
essential	O
hypertension-43	BP
and	O
myocardial	BP
infarction-46	IP
.	O

PS2008	O
There	O
is	O
a	O
correlation	O
between	O
the	O
decreasing	O
activity	O
of	O
NAT2	BG
gene	IG
product-12	IG
and	O
the	O
sensitivity	O
to	O
harmful	O
environmental	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
occurrence	O
of	O
different	O
multifactorial	O
diseases	O
,	O
including	O
dermatological	O
ones	O
like	O
psoriasis-35	BP
.	O

PS2010	O
Mutations	O
of	O
the	O
CYP4V2	BG
gene-5	IG
,	O
a	O
novel	O
family	O
member	O
of	O
the	O
cytochrome	BG
P450	IG
genes-15	IG
on	O
chromosome	O
4q35	O
,	O
have	O
recently	O
been	O
identified	O
in	O
patients	O
with	O
Bietti	O
crystalline	BP
dystrophy-29	IP
.	O

PS2012	O
In	O
a	O
previous	O
study	O
,	O
we	O
identified	O
a	O
TNFP	BG
-	IG
allele-11	IG
characterized	O
by	O
a	O
C	O
to	O
T	O
transition	O
at	O
position	O
-	O
857	O
(	O
TNFP	BG
-	IG
D	IG
allele-27	IG
)	O
as	O
a	O
marker	O
for	O
susceptibility	O
to	O
cerebral	BP
malaria-36	IP
in	O
Myanmar	O
.	O

PS2023	O
MyBPC3-1	BG
mutations	O
are	O
amongst	O
the	O
most	O
frequent	O
causes	O
of	O
hypertrophic	BP
cardiomyopathy-11	IP
,	O
however	O
,	O
its	O
prevalence	O
varies	O
between	O
populations	O
.	O

PS2028	O
Subsequent	O
studies	O
indicated	O
that	O
FOXP3-5	BG
is	O
a	O
key	O
transcription	O
factor	O
indispensable	O
for	O
regulatory	O
functions	O
of	O
T	O
cells	O
pointing	O
to	O
a	O
critical	O
role	O
of	O
regulatory	O
T	O
-	O
cell	O
homeostasis	O
in	O
the	O
development	O
of	O
Autoimmune	BP
enteropathy-34	IP
.	O

PS2033	O
Germline	O
mutations	O
of	O
the	O
tumor	O
suppressor	O
gene	O
LKB1-8	BG
/	O
STK11-10	BG
are	O
responsible	O
for	O
the	O
Peutz	O
-	O
Jeghers	O
syndrome	O
,	O
an	O
autosomal	O
-	O
dominant	O
disorder	O
characterized	O
by	O
mucocutaneous	O
pigmentation-28	BP
,	O
hamartomatous	O
polyps	O
,	O
and	O
an	O
increased	O
risk	O
of	O
associated	O
malignancies-39	BP
.	O

PS2041	O
The	O
coding	O
regions	O
of	O
6	O
genes	O
that	O
cause	O
peripheral	BP
neuropathy-10	IP
and	O
regions	O
of	O
the	O
muscle	O
sodium	O
channel	O
gene	O
(	O
SCN4A-20	BG
)	O
were	O
sequenced	O
.	O

PS2053	O
In	O
conclusion	O
,	O
it	O
was	O
found	O
that	O
mutations	O
in	O
the	O
SH2D1A	BG
gene-12	IG
are	O
responsible	O
for	O
X	O
-	O
linked	O
lymphoproliferative	BP
disease-20	IP
but	O
that	O
there	O
is	O
no	O
correlation	O
between	O
genotype	O
and	O
phenotype	O
or	O
outcome	O
.	O

PS2054	O
We	O
studied	O
the	O
involvement	O
of	O
GLI3-6	BG
in	O
additional	O
phenotypes	O
of	O
digital	BP
abnormalities-12	IP
in	O
one	O
family	O
(	O
UR003	O
)	O
with	O
preaxial	BP
polydactyly-21	IP
type	O
-	O
IV	O
,	O
three	O
families	O
(	O
UR014	O
,	O
UR015	O
,	O
and	O
UR016	O
)	O
with	O
dominant	O
polydactyly	O
type	O
-	O
A	O
/	O
B	O
(	O
with	O
PPD	O
-	O
A	O
and	O
-	O
B	O
in	O
the	O
same	O
family	O
)	O
,	O
and	O
one	O
family	O
with	O
Pallister	O
-	O
Hall	O
syndrome	O
.	O

PS2060	O
Polymerase	O
chain	O
reaction	O
-	O
restriction	O
polymorphism	O
length	O
fragment	O
and	O
direct	O
sequencing	O
of	O
exon	O
2	O
and	O
the	O
coding	O
region	O
of	O
exon	O
3	O
of	O
CYP1B1	BG
gene-24	IG
were	O
the	O
methods	O
used	O
for	O
screening	O
17	O
primary	O
congenital	O
glaucoma-34	BP
patients	O
,	O
their	O
families	O
,	O
and	O
105	O
health	O
individuals	O
from	O
the	O
same	O
ethnicity	O
.	O

PS2064	O
Carnitine	BG
palmitoyl	IG
transferase	IG
II-4	IG
deficiency	O
,	O
an	O
inherited	O
disorder	O
of	O
long	O
-	O
chain	O
fatty	O
acid	O
oxidation	O
,	O
may	O
result	O
in	O
either	O
a	O
mild	O
form	O
(	O
muscle	BP
disease-27	IP
in	O
adults	O
)	O
or	O
a	O
severe	O
form	O
(	O
hepatocardiomuscular	O
syndrome	O
in	O
infants	O
)	O
.	O

PS2066	O
In	O
this	O
study	O
we	O
describe	O
evidence	O
for	O
the	O
alternative	O
lengthening	O
of	O
telomeres	O
phenotype	O
in	O
molecular	O
subclasses	O
of	O
breast	BP
carcinoma-19	IP
,	O
specifically	O
a	O
subset	O
of	O
cancers-25	BP
with	O
HER	BG
-	IG
2-29	IG
overexpression	O
.	O

PS2067	O
As	O
cancers-2	BP
using	O
the	O
alternative	O
lengthening	O
of	O
telomeres	O
pathway	O
are	O
predicted	O
to	O
be	O
resistant	O
to	O
therapies	O
based	O
on	O
telomerase-19	BG
inhibition	O
,	O
these	O
results	O
may	O
have	O
therapeutic	O
consequences	O
.	O

PS2068	O
In	O
the	O
stronger	O
allele	O
(	O
110	O
bp	O
insert	O
)	O
ribosomal	O
protein	O
S3	BG
mRNA-13	IG
levels	O
are	O
reduced	O
by	O
approximately	O
60	O
%	O
,	O
resulting	O
in	O
an	O
extreme	O
Minute	O
phenotype	O
that	O
includes	O
many	O
moribosomal	O
proteinhological	O
abnormalities	O
as	O
well	O
as	O
sterility	O
in	O
both	O
males	O
and	O
females	O
due	O
to	O
disruption	O
of	O
early	BP
gametogenesis-48	IP
.	O

PS2069	O
Progressive	O
demyelination	O
occurs	O
in	O
metachromatic	O
leukodystrophy	O
,	O
while	O
the	O
condition	O
of	O
Arylsulfatase	BG
A	IG
-	IG
pseudodeficiency-15	IG
(	O
Arylsulfatase	BG
A	IG
-	IG
PD-20	IG
)	O
is	O
suggested	O
to	O
contribute	O
to	O
complex	O
pathogenesis	BP
of	IP
multiple	IP
sclerosis-31	IP
.	O

PS2075	O
decrease	O
of	O
alpha	BG
-	IG
glucosidase-5	IG
activity	O
is	O
the	O
final	O
common	O
pathway	O
leading	O
to	O
destruction	O
of	O
muscle	O
fibers	O
and	O
progression	O
of	O
muscle	BP
weakness-22	IP
over	O
a	O
period	O
of	O
years	O
.	O

PS2080	O
Its	O
male	O
predominance	O
,	O
the	O
absence	O
of	O
Loss	O
of	O
heterozygosity	O
in	O
the	O
multiple	O
endocrine	O
neoplasia-15	BP
type	O
1	O
region	O
,	O
clustering	O
in	O
close	O
relatives	O
,	O
and	O
the	O
presence	O
of	O
different	O
multiple	O
endocrine	O
neoplasia-32	BP
type	O
1	O
mutations	O
in	O
these	O
families	O
suggest	O
the	O
involvement	O
of	O
modifying	O
genes	O
in	O
addition	O
to	O
the	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
1	IG
gene-54	IG
.	O

PS2087	O
A	O
missense	O
mutation	O
in	O
the	O
exon	O
7	O
of	O
the	O
cardiac	BG
troponin	IG
I	IG
gene-13	IG
was	O
identified	O
in	O
a	O
40	O
-	O
year	O
-	O
old	O
male	O
patient	O
with	O
hypertrophic	BP
cardiomyopathy-27	IP
(	O
Asp127Tyr	O
)	O
which	O
was	O
absent	O
in	O
the	O
controls	O
.	O

PS2108	O
There	O
is	O
convincing	O
epidemiological	O
evidence	O
that	O
lung	O
cancer-8	BP
risk	O
associated	O
with	O
polycyclic	O
aromatic	O
hydrocarbons	O
is	O
mediated	O
in	O
part	O
by	O
aryl	BG
hydrocarbon	IG
hydroxylase-22	IG
,	O
which	O
is	O
used	O
as	O
an	O
indicator	O
of	O
the	O
phenotype	O
of	O
CYP1A1-34	BG
.	O

PS2111	O
A	O
close	O
association	O
between	O
development	O
of	O
lung	O
cancer-8	BP
and	O
homozygous	O
rare	O
genotypes	O
in	O
MspI-14	BG
and	O
Ile	BG
-	IG
Val	IG
polymorphisms-19	IG
of	O
CYP1A1	BG
gene-22	IG
has	O
been	O
recently	O
reported	O
in	O
some	O
Japanese	O
populations	O
.	O

PS2114	O
Risk	O
of	O
lung	O
cancer-4	BP
,	O
especially	O
squamous	BP
cell	IP
carcinoma-9	IP
is	O
shown	O
to	O
be	O
remarkably	O
increased	O
in	O
individuals	O
with	O
a	O
combination	O
of	O
a	O
homozygous	O
rare	O
allele	O
of	O
the	O
CYP1A1	BG
gene-29	IG
and	O
the	O
nulled	BG
GSTM1	IG
gene-34	IG
,	O
compared	O
with	O
those	O
having	O
other	O
combinations	O
of	O
genotypes	O
.	O

PS2115	O
Correlations	O
between	O
specific	O
binding	O
of	O
labeled	O
adrenoligands	O
in	O
the	O
frontal	O
cortex	O
and	O
hypothalamus-13	BP
and	O
peripheral	O
blood	O
plasma	O
testosterone	O
were	O
studied	O
in	O
BALB	O
/	O
cLac-24	BG
,	O
CBA-26	BG
/	O
Lac-28	BG
,	O
and	O
S57BL	O
/	O
6J	O
male	O
mice	O
.	O

PS2127	O
Other	O
mutations	O
in	O
ROR2-4	BG
result	O
in	O
the	O
autosomal	O
dominant	O
disease	O
,	O
brachydactyly-12	BP
type	O
B	O
(	O
BDB1	O
)	O
.	O

PS2128	O
To	O
characterize	O
a	O
large	O
family	O
with	O
MEN1-7	BG
with	O
aggressive	BP
tumour	IP
behaviour-11	IP
:	O
malignant	O
pancreatic	O
endocrine	O
tumours	O
were	O
present	O
in	O
five	O
affected	O
subjects	O
and	O
were	O
the	O
presenting	O
features	O
in	O
three	O
subjects	O
.	O

PS2141	O
The	O
presence	O
of	O
the	O
-	O
112G	O
/	O
A	O
polymorphism	O
in	O
the	O
Uteroglobin	BG
-	IG
related	IG
protein	IG
1	IG
promoter-17	IG
was	O
found	O
to	O
have	O
a	O
significant	O
correlation	O
with	O
asthma-26	BP
phenotype	O
.	O

PS2152	O
spinal	BP
muscular	IP
atrophy-3	IP
is	O
caused	O
by	O
mutations	O
in	O
the	O
survival	O
motor	O
neuron	O
telomeric	O
gene	O
(	O
SMN1-16	BG
)	O
and	O
a	O
centromeric	O
functional	O
copy	O
of	O
this	O
gene	O
(	O
SMN2-27	BG
)	O
exists	O
,	O
both	O
genes	O
being	O
located	O
at	O
5q13	O
.	O

PS2160	O
Mutations	O
in	O
the	O
cardiac	BG
myosin	IG
-	IG
binding	IG
protein	IG
C-9	IG
(	O
MYBPC3-11	BG
)	O
gene	O
are	O
frequently	O
found	O
as	O
a	O
cause	O
of	O
hypertrophic	BP
cardiomyopathy-22	IP
.	O

PS2173	O
We	O
found	O
a	O
novel	O
germline	O
frameshift	O
mutation	O
(	O
757	O
-	O
758insT	O
)	O
in	O
the	O
LKB1	BG
gene-16	IG
and	O
a	O
marked	O
reduction	O
in	O
LKB1	BG
protein-23	IG
expression	O
in	O
the	O
carcinoma	O
cells	O
,	O
suggesting	O
that	O
the	O
loss	O
of	O
LKB1-35	BG
function	O
may	O
have	O
led	O
to	O
the	O
carcinogenesis	O
of	O
the	O
gastric	BP
cancer-46	IP
.	O

PS2184	O
Our	O
results	O
suggest	O
that	O
N	BG
-	IG
acetyltransferase1-7	IG
and	O
N	BG
-	IG
acetyltransferase2	IG
gene-12	IG
combinations	O
may	O
influence	O
the	O
risk	O
of	O
developing	O
head	O
and	O
neck	O
cancer-23	BP
.	O

PS2189	O
The	O
present	O
study	O
examined	O
whether	O
the	O
-	O
1612	O
5A	O
/	O
6A	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
Matrix	BG
metalloproteinase	IG
-	IG
3	IG
gene-23	IG
influences	O
serum	O
concentrations	O
of	O
Matrix	BG
metalloproteinase	IG
-	IG
3-31	IG
and	O
whether	O
serum	O
concentrations	O
of	O
Matrix	BG
metalloproteinase	IG
-	IG
3-40	IG
are	O
related	O
to	O
extent	O
of	O
coronary	O
atherosclerosis	O
and	O
risk	O
of	O
myocardial	BP
infarction-52	IP
.	O

PS2192	O
Depending	O
on	O
the	O
clinical	O
severity	O
,	O
Mevalonate	BG
kinase	IG
deficiency-9	IP
may	O
present	O
as	O
hyper	O
-	O
IgD-15	BG
and	O
periodic	O
fever-18	BP
syndrome	O
or	O
the	O
more	O
severe	O
mevalonic	BP
aciduria-25	IP
.	O

PS2204	O
Autosomal	O
dominant	O
hereditary	O
spastic	BP
paraplegia-5	IP
is	O
mainly	O
caused	O
by	O
mutations	O
in	O
the	O
SPG4	BG
gene-14	IG
,	O
which	O
encodes	O
a	O
new	O
member	O
of	O
the	O
associated	O
with	O
diverse	O
cellular	O
activities	O
(	O
adenosine	O
triphosphatases	O
associated	O
with	O
diverse	O
cellular	O
activities	O
)	O
protein	O
family	O
(	O
spastin-40	BG
)	O
.	O

PS2231	O
In	O
contrast	O
,	O
her	O
mother	O
had	O
developed	O
a	O
generalized	O
myopathy-10	BP
without	O
progressive	BP
external	IP
ophthalmoplegia-14	IP
,	O
morphologically	O
characterized	O
by	O
many	O
cytochrome	BG
-	IG
c	IG
oxidase-23	IG
-	O
negative	O
ragged	O
red	O
fibers	O
.	O

PS2236	O
Mutations	O
in	O
TRPV4-3	BG
,	O
a	O
gene	O
that	O
encodes	O
a	O
Ca	O
(	O
2	O
+	O
)	O
permeable	O
non	O
-	O
selective	O
cation	O
channel	O
,	O
have	O
recently	O
been	O
found	O
in	O
a	O
spectrum	O
of	O
skeletal	O
dysplasias	O
that	O
includes	O
brachyolmia-34	BP
,	O
spondylometaphyseal	BP
dysplasia-37	IP
,	O
Kozlowski	O
type	O
(	O
Smetatropic	BG
dysplasiaK-43	IG
)	O
and	O
metatropic	BP
dysplasia-47	IP
.	O

PS2237	O
In	O
metatropic	BP
dysplasia-3	IP
,	O
a	O
recurrent	O
P799L	BG
mutation-8	IG
was	O
identified	O
in	O
nine	O
subjects	O
,	O
as	O
well	O
as	O
10	O
novel	O
mutations	O
including	O
F471del-22	BG
,	O
the	O
first	O
deletion	O
mutation	O
of	O
TRPV4-29	BG
.	O

PS2239	O
It	O
was	O
found	O
that	O
microsatellite	BG
instability-6	IG
and	O
p53	BG
gene-9	IG
mutation	O
involve	O
two	O
distinct	O
subsets	O
of	O
both	O
early	O
and	O
advanced	O
-	O
stage	O
glandular	O
(	O
intestinal	O
)	O
cancer-26	BP
,	O
and	O
that	O
,	O
contrastingly	O
,	O
they	O
leave	O
purely	O
diffuse	O
cancers-37	BP
unaffected	O
.	O

PS2250	O
Acute	BP
intermittent	IP
porphyria-3	IP
,	O
resulting	O
from	O
a	O
deficiency	O
of	O
porphobilinogen	BG
deaminase-11	IG
in	O
heme	O
biosynthesis	O
,	O
is	O
genetically	O
heterogeneous	O
and	O
manifests	O
with	O
variable	O
penetrance	O
.	O

PS2265	O
Thereby	O
,	O
in	O
sporadic	O
gastric	BP
cancer-6	IP
microsatellite	O
instability	O
is	O
caused	O
by	O
loss	O
of	O
hMLH1-14	BG
expression	O
due	O
to	O
hypermethylation	O
of	O
the	O
promotor	O
region	O
rather	O
than	O
by	O
mutation	O
of	O
the	O
gene	O
itself	O
.	O

PS2269	O
In	O
nine	O
unrelated	O
Portuguese	O
patients	O
with	O
pyruvate	BG
kinase-8	IG
deficient	O
anaemia-10	BP
,	O
whose	O
symptoms	O
ranged	O
from	O
a	O
mild	O
chronic	O
haemolytic	O
anaemia	O
to	O
a	O
severe	O
anaemia	O
presenting	O
at	O
birth	O
and	O
requiring	O
multiple	O
transfusions	O
,	O
the	O
pyruvate	BG
kinase	IG
-	IG
LR	IG
gene-38	IG
mutations	O
were	O
identified	O
and	O
correlated	O
with	O
their	O
phenotypes	O
.	O

PS2274	O
Even	O
in	O
the	O
absence	O
of	O
genetic	O
testing	O
,	O
African	O
-	O
American	O
men	O
and	O
men	O
with	O
a	O
strong	O
family	O
history	O
of	O
prostate	BP
cancer-22	IP
may	O
opt	O
to	O
initiate	O
screening	O
by	O
prostate	BG
specific	IG
antigen-31	IG
and	O
digital	O
rectal	O
exam	O
screening	O
at	O
age	O
40	O
.	O

PS2283	O
Synpolydactyly-1	BP
is	O
a	O
rare	O
congenital	BP
limb	IP
disorder-7	IP
caused	O
by	O
mutations	O
in	O
the	O
HOXD13	BG
gene-14	IG
,	O
a	O
homeobox	BG
transcription	IG
factor-19	IG
crucial	O
for	O
autopod	O
development	O
.	O

PS2289	O
Hyperphenylalaninemia	O
,	O
which	O
includes	O
phenylketonuria-5	BP
,	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
phenylalanine	BG
hydroxylase-16	IG
,	O
being	O
already	O
described	O
more	O
than	O
600	O
different	O
mutations	O
.	O

PS2293	O
In	O
the	O
present	O
article	O
,	O
we	O
evaluated	O
changes	O
in	O
human	O
immunodeficiency-11	BP
virus	O
type	O
1	O
viral	O
fitness	O
associated	O
with	O
the	O
sequential	O
introduction	O
of	O
antiretroviral	O
treatment	O
strategies	O
in	O
4	O
chronically	O
infected	O
patients	O
with	O
sustained	O
CD4-33	BG
cell	O
count	O
despite	O
having	O
a	O
persistently	O
detectable	O
viral	O
load	O
.	O

PS2297	O
ESR1	BG
gene-2	IG
alleles	O
are	O
unlikely	O
to	O
be	O
a	O
major	O
cause	O
of	O
obesity-12	BP
in	O
women	O
.	O

PS2326	O
Polymorphic	O
markers	O
of	O
ACE-4	BG
and	O
GNB3-6	BG
candidate	O
genes	O
influence	O
clinical	O
diversity	O
of	O
pathological	O
signs	O
in	O
diabetes	BP
mellitus-17	IP
type	O
2	O
patients	O
through	O
modification	O
of	O
arterial	O
hypertension-25	BP
and	O
left	O
ventricular	O
hypertrophy	O
severity	O
and	O
the	O
level	O
of	O
proinflammatory	O
cytokines	O
.	O

PS2328	O
Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
FOXL2-8	BG
are	O
predicted	O
to	O
lead	O
to	O
BPES	O
and	O
premature	O
ovarian	BP
failure-18	IP
,	O
while	O
hypomorphic	O
mutations	O
might	O
lead	O
to	O
BPES	O
without	O
ovarian	O
dysfunction	O
.	O

PS2332	O
Some	O
studies	O
have	O
revealed	O
predisposing	O
or	O
protective	O
HLA	BG
genes-9	IG
for	O
Posttransplantation	BP
diabetes-12	IP
mellitus	O
.	O

PS2336	O
SH2D1A	BG
gene-2	IG
defects	O
are	O
the	O
cause	O
of	O
X	O
-	O
linked	O
lymphoproliferative	BP
disorder-12	IP
(	O
XLP	O
-	O
1	O
)	O
,	O
a	O
rare	O
condition	O
characterized	O
by	O
severe	O
immune	BP
dysregulation-26	IP
.	O

PS2347	O
To	O
determine	O
the	O
mutational	O
spectrum	O
in	O
the	O
Hungarian	O
Congenital	BP
adrenal	IP
hyperplasia-11	IP
population	O
,	O
the	O
CYP21-15	BG
active	O
gene	O
was	O
analyzed	O
using	O
PCR	O
.	O

PS2348	O
Two	O
divergent	O
phenotypes	O
were	O
observed	O
:	O
one	O
with	O
prevalent	O
expression	O
of	O
cancer-12	BP
testis	O
antigens	O
,	O
enhanced	O
cyclin-17	BG
activity	O
,	O
WNT-20	BG
signaling	O
,	O
and	O
a	O
Th17	O
immune	O
phenotype	O
(	O
Class	O
A	O
)	O
.	O

PS2349	O
The	O
second	O
class	O
(	O
B	O
)	O
prevalently	O
expressed	O
genes	O
associated	O
with	O
melanoma-12	BP
signaling	O
including	O
MITF-15	BG
,	O
melanoma-17	BP
differentiation	O
antigens	O
,	O
and	O
displayed	O
a	O
Th1	O
immune	O
phenotype	O
associated	O
with	O
better	O
prognosis	O
and	O
likelihood	O
to	O
respond	O
to	O
immunotherapy	O
.	O

PS2355	O
Zidovudine	BP
resistance-2	IP
is	O
associated	O
with	O
classic	O
genotypic	O
changes	O
at	O
codons	O
41	O
,	O
67	O
,	O
70	O
,	O
210	O
,	O
215	O
,	O
and	O
219	O
of	O
the	O
human	BG
immunodeficiency	IG
virus	IG
type	IG
1	IG
reverse	IG
transcriptase-31	IG
gene	O
as	O
well	O
as	O
with	O
the	O
multinucleoside	BP
resistance-39	IP
complexes	O
.	O

PS2359	O
Zidovudine	BP
resistance-2	IP
is	O
associated	O
with	O
classic	O
genotypic	O
changes	O
at	O
codons	O
41	O
,	O
67	O
,	O
70	O
,	O
210	O
,	O
215	O
,	O
and	O
219	O
of	O
the	O
human	BG
immunodeficiency	IG
virus	IG
type	IG
1	IG
reverse	IG
transcriptase-31	IG
gene	O
as	O
well	O
as	O
with	O
the	O
multinucleoside	BP
resistance-39	IP
complexes	O
.	O

PS2379	O
An	O
inverse	O
correlation	O
between	O
the	O
expression	O
of	O
miR	BG
-	IG
155-10	IG
and	O
the	O
expression	O
of	O
MLH1-15	BG
or	O
MSH2	BG
proteins-18	IG
was	O
found	O
in	O
human	O
colorectal	BP
cancer-24	IP
.	O

PS2386	O
Argininosuccinic	O
aciduria	O
is	O
an	O
inborn	O
error	O
of	O
metabolism	O
caused	O
by	O
mutations	O
in	O
the	O
argininosuccinate	BG
lyase-15	IG
gene	O
,	O
which	O
leads	O
to	O
the	O
accumulation	O
of	O
argininosuccinic	O
acid	O
in	O
body	O
fluids	O
and	O
severe	O
hyperammonemia-31	BP
.	O

PS2398	O
Hereditary	O
spastic	BP
paraplegia-3	IP
type	O
6	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
NIPA1	BG
gene-13	IG
,	O
this	O
is	O
a	O
rare	O
cause	O
of	O
HSP	O
,	O
until	O
now	O
,	O
all	O
the	O
affected	O
individuals	O
reported	O
displayed	O
"	O
pure	O
"	O
spastic	BP
paraplegia-36	IP
.	O

PS2407	O
Failure-1	BP
to	O
thrive	O
,	O
prominent	BP
forehead-6	IP
,	O
exophthalmia-8	BP
,	O
optic	BP
atrophy-11	IP
,	O
hepatosplenomegaly	O
,	O
neurological	O
manifestations	O
,	O
anaemia-18	BP
,	O
thrombocytopenia-20	BP
,	O
hypocalcaemia-22	BP
,	O
elevated	O
hepatic	O
enzymes	O
and	O
acid	BG
phosphatase-29	IG
,	O
and	O
an	O
early	O
fatal	O
outcome	O
were	O
common	O
.	O

PS2409	O
Epidermolysis	O
bullosa	O
simplex	O
is	O
a	O
mechanobullous	O
genodermatosis-7	BP
that	O
may	O
be	O
caused	O
by	O
mutations	O
in	O
the	O
genes	O
KRT5-17	BG
and	O
KRT14-19	BG
encoding	O
the	O
basal	O
epidermal	O
keratins	O
5	O
and	O
14	O
(	O
K14	O
)	O
.	O

PS2427	O
Studies	O
investigating	O
the	O
genetic	O
control	O
of	O
total	O
serum	O
IgE-9	BG
levels	O
are	O
of	O
major	O
importance	O
in	O
understanding	O
basic	O
pathophysiologic	O
mechanisms	O
in	O
atopy	O
and	O
asthma-23	BP
,	O
since	O
IgE-26	BG
levels	O
predict	O
onset	O
and	O
correlate	O
with	O
the	O
clinical	O
expression	O
of	O
these	O
disorders	O
.	O

PS2435	O
Human	BG
Filamin	IG
A	IG
gene-4	IG
mutations	O
are	O
associated	O
with	O
classical	O
X	O
-	O
linked	O
bilateral	O
periventricular	O
nodular	O
heterotopia	O
,	O
featuring	O
contiguous	O
heterotopic	O
nodules	O
,	O
mega	O
cisterna	O
magna	O
,	O
cardiovascular	O
malformations	O
and	O
epilepsy-30	BP
.	O

PS2440	O
Specifically	O
,	O
mutations	O
in	O
the	O
H1	O
and	O
alpha	O
-	O
helical	O
rod	O
domains	O
of	O
K1-14	BG
/	O
K10-16	BG
result	O
in	O
bullous	O
congenital	O
ichthyosiform	O
erythroderma-22	BP
,	O
underscoring	O
the	O
critical	O
role	O
for	O
this	O
keratin	O
filament	O
domain	O
in	O
maintaining	O
cellular	O
integrity	O
.	O

PS2456	O
Thus	O
,	O
intranuclear	BP
aggregation-4	IP
and	O
cytoplasmic	O
mislocalization	O
of	O
mutant	O
FOXL2-10	BG
may	O
be	O
considered	O
as	O
loose	O
predictors	O
of	O
ovarian	BP
dysfunction-19	IP
.	O

PS2463	O
However	O
,	O
large	O
comprehensive	O
genotyping	O
studies	O
,	O
evaluated	O
under	O
clinical	O
settings	O
,	O
are	O
still	O
needed	O
to	O
unravel	O
the	O
potential	O
impact	O
of	O
aromatase-22	BG
inhibitor	O
pharmacogenomics	O
on	O
breast	BP
cancer-27	IP
treatment	O
,	O
monitoring	O
and	O
predicting	O
adverse	O
effects	O
.	O

PS2479	O
Limb	O
girdle	O
muscular	BP
dystrophies2A-4	IP
,	O
the	O
most	O
prevalent	O
form	O
of	O
Limb	O
girdle	O
muscular	BP
dystrophies-14	IP
,	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
calpain	BG
-	IG
3	IG
gene-25	IG
.	O

PS2480	O
The	O
associated	O
hyperphenylalaninemia-3	BP
phenotype	O
is	O
highly	O
variable	O
,	O
primarily	O
due	O
to	O
great	O
allelic	O
heterogeneity	O
in	O
the	O
PAH	BG
locus-18	IG
.	O

PS2497	O
The	O
distribution	O
of	O
PTPN22	BG
alleles-5	IG
and	O
genotypes	O
among	O
patients	O
and	O
controls	O
was	O
compared	O
,	O
and	O
correlation	O
was	O
sought	O
between	O
PTPN22-20	BG
'	O
T	O
'	O
and	O
sex	O
,	O
tobacco	O
smoking	O
status	O
,	O
family	O
history	O
of	O
Graves	O
'	O
disease	O
,	O
age	O
of	O
disease	O
onset	O
,	O
presence	O
(	O
and	O
severity	O
)	O
of	O
ophthalmopathy-49	BP
,	O
and	O
presence	O
of	O
the	O
CTLA4	BG
A49G-56	IG
or	O
DRB1	BG
*	IG
03	IG
alleles-61	IG
.	O

PS2507	O
Cystic	BP
fibrosis-2	IP
is	O
an	O
autosomal	O
recessive	O
disease	O
that	O
may	O
be	O
caused	O
by	O
more	O
than	O
1000	O
different	O
mutations	O
in	O
the	O
cystic	BG
fibrosis	IG
transmembrane	IG
conductance	IG
regulator-24	IG
gene	O
.	O

PS2508	O
Phenylketonuria-1	BP
and	O
hyperphenylalaninemia-3	BP
are	O
caused	O
mostly	O
by	O
an	O
inherited	O
(	O
autosomal	O
recessive	O
)	O
deficiency	O
in	O
hepatic-16	BP
phenylalanine	BG
hydroxylase-18	IG
activity	O
.	O

PS2528	O
Hypertrophic	BP
cardiomyopathy-2	IP
and	O
dilated	BP
cardiomyopathy-5	IP
can	O
both	O
be	O
due	O
to	O
mutations	O
in	O
the	O
genes	O
encoding	O
alpha	O
-	O
myosin	BG
heavy	IG
chain	IG
(	IG
MYH7	IG
)	IG
or	IG
cardiac	IG
myosin	IG
-	IG
binding	IG
protein	IG
C-30	IG
(	O
MYBPC3-32	BG
)	O
.	O

PS2543	O
Genetic	O
alterations	O
in	O
the	O
gene	O
encoding	O
for	O
endothelial	BG
nitric	IG
oxide	IG
synthase-11	IG
could	O
contribute	O
to	O
the	O
development	O
and	O
progression	O
of	O
coronary	BP
artery	IP
disease-22	IP
.	O

PS2551	O
In	O
order	O
to	O
evaluate	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
the	O
Pancreatic	BP
Insufficiency-12	IP
Prevalence	O
score	O
was	O
developed	O
and	O
validated	O
to	O
determine	O
severity	O
in	O
a	O
large	O
number	O
of	O
cystic	BG
fibrosis	IG
transmembrane	IG
conductance	IG
regulator	IG
mutations-32	IG
.	O

PS2560	O
The	O
nerve	BG
growth	IG
factor	IG
beta-5	IG
mutation	O
in	O
its	O
heterozygous	O
form	O
results	O
in	O
a	O
milder	O
disease	O
than	O
in	O
homozygotes	O
,	O
with	O
a	O
variable	O
clinical	O
picture	O
,	O
ranging	O
from	O
asymptomatic	O
cases	O
to	O
those	O
with	O
Charcot	O
arthropathy-34	BP
appearing	O
in	O
adult	O
age	O
.	O

PS2562	O
Impaired	BP
virilisation-2	IP
during	O
embryonic	O
development	O
and	O
pubertal	O
arrest	O
in	O
patients	O
with	O
androgen	O
insensitivity	O
syndromes	O
is	O
usually	O
caused	O
by	O
mutations	O
in	O
the	O
androgen	BG
receptor-23	IG
-	O
or	O
the	O
5alpha	BG
-	IG
reductase	IG
II-30	IG
gene	O
.	O

PS2564	O
Mutations	O
of	O
the	O
iduronate	BG
-	IG
2	IG
-	IG
sulfatase	IG
gene-9	IG
have	O
been	O
identified	O
as	O
responsible	O
of	O
Hunter	O
syndrome	O
or	O
mucopolysaccharidosis-19	BP
type	O
II	O
.	O

PS2576	O
The	O
major	O
cause	O
of	O
congenital	BP
adrenal	IP
hyperplasia-7	IP
is	O
21	O
-	O
hydroxylase-11	BG
deficiency	O
,	O
which	O
accounts	O
for	O
90	O
%	O
-	O
95	O
%	O
of	O
all	O
cases	O
in	O
most	O
populations	O
.	O

PS2594	O
Mutations	O
in	O
protein	BG
O	IG
-	IG
mannosyltransferases-6	IG
cause	O
a	O
heterogeneous	O
group	O
of	O
muscular	O
dystrophies	O
with	O
abnormal	O
glycosylation	O
of	O
alpha	O
-	O
dystroglycan	O
(	O
dystroglycanopathies-22	BP
)	O
.	O

PS2602	O
Mutations	O
in	O
the	O
ectodysplasin	BG
-	IG
A-6	IG
gene	O
can	O
cause	O
both	O
X	O
-	O
linked	O
hypohidrotic	BP
ectodermal	IP
dysplasia-16	IP
and	O
non	O
-	O
syndromic	O
hypodontia-21	BP
.	O

PS2612	O
Genome	O
-	O
wide	O
association	O
studies	O
recently	O
identified	O
a	O
novel	O
gene	O
,	O
TRAF3IP2-12	BG
,	O
involved	O
in	O
the	O
susceptibility	O
to	O
psoriasis-19	BP
.	O

PS2631	O
Pathogenic	BG
GUCY2D-2	IG
mutations	O
result	O
in	O
the	O
most	O
severe	O
form	O
of	O
Leber	O
congenital	BP
amaurosis-13	IP
.	O

PS2632	O
Several	O
structural	O
mutations	O
of	O
UGT1A1-5	BG
,	O
for	O
example	O
,	O
a	O
G71R	O
substitution	O
,	O
have	O
been	O
reported	O
to	O
cause	O
mild	O
reduction	O
of	O
UGT	O
activity	O
toward	O
bilirubin	O
,	O
resulting	O
in	O
mild	O
hyperbilirubinemia-30	BP
,	O
consistent	O
with	O
Gilbert	O
syndrome	O
.	O

PS2633	O
Since	O
there	O
has	O
been	O
only	O
one	O
report	O
of	O
this	O
link	O
,	O
it	O
was	O
decided	O
to	O
investigate	O
the	O
susceptibility	O
of	O
cytochrome	BG
P450	IG
2E1	IG
enzyme-23	IG
to	O
Nasopharyngeal	BP
carcinoma-26	IP
development	O
in	O
other	O
populations	O
.	O

PS2639	O
The	O
importance	O
of	O
genetic	O
variability	O
of	O
the	O
components	O
of	O
mismatch	BG
repair	IG
genes-12	IG
is	O
well	O
documented	O
in	O
colorectal	BP
cancer-18	IP
,	O
but	O
little	O
is	O
known	O
about	O
its	O
role	O
in	O
breast	BP
cancer-29	IP
.	O

PS2640	O
We	O
performed	O
a	O
case	O
-	O
control	O
study	O
to	O
test	O
the	O
association	O
between	O
two	O
polymorphisms	O
in	O
the	O
hMSH2	BG
gene-18	IG
:	O
an	O
A	O
-	O
-	O
>	O
G	O
transition	O
at	O
127	O
position	O
producing	O
an	O
Asn	O
-	O
-	O
>	O
Ser	O
substitution	O
at	O
codon	O
127	O
(	O
the	O
Asn127Ser	O
polymorphism	O
)	O
and	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
1032	O
position	O
resulting	O
in	O
a	O
Gly	O
-	O
-	O
>	O
Asp	O
change	O
at	O
codon	O
322	O
(	O
the	O
Gly322Asp	O
polymorphism	O
)	O
and	O
breast	BP
cancer-76	IP
risk	O
and	O
cancer-79	BP
progression	O
.	O

PS2695	O
In	O
this	O
large	O
Dutch	O
cohort	O
,	O
we	O
seem	O
to	O
have	O
identified	O
the	O
first	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
spastic	BP
paraplegia-20	IP
type	O
7	O
by	O
observing	O
an	O
association	O
between	O
the	O
cerebellar	O
phenotype	O
of	O
spastic	BP
paraplegia-33	IP
type	O
7	O
and	O
SPG7-37	BG
null	O
alleles	O
.	O

PS2698	O
Angiotensin	BG
II-2	IG
,	O
which	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
myocardial	O
remodeling	O
process	O
of	O
heart	BP
failure-16	IP
,	O
is	O
generated	O
via	O
the	O
angiotensin	BG
-	IG
converting	IG
enzyme-25	IG
and	O
chymase-27	BG
pathways	O
.	O

PS2708	O
The	O
results	O
showed	O
that	O
glutamate	O
was	O
accumulated	O
in	O
the	O
rds	O
/	O
rds	O
mouse	O
photoreceptor	O
inner	O
segment	O
,	O
suggesting	O
that	O
glutamate	O
may	O
play	O
a	O
role	O
in	O
the	O
process	O
of	O
retinal	BP
degeneration-30	IP
caused	O
by	O
the	O
peripherin	BG
/	IG
RDS	IG
gene-37	IG
abnormality	O
,	O
although	O
the	O
precise	O
mechanism	O
is	O
currently	O
unknown	O
.	O

PS2709	O
Defect	O
of	O
growth	BG
hormone	IG
receptor-5	IG
is	O
classically	O
known	O
to	O
cause	O
Laron	O
syndrome	O
,	O
characterized	O
by	O
short	BP
stature-17	IP
,	O
specific	O
facial	O
appearance	O
,	O
elevated	O
serum	BG
growth	IG
hormone-26	IG
levels	O
,	O
and	O
decreased	O
insulin	BG
-	IG
like	IG
growth	IG
factor	IG
I-36	IG
levels	O
.	O

PS2711	O
Defect	O
of	O
growth	BG
hormone	IG
receptor-5	IG
is	O
classically	O
known	O
to	O
cause	O
Laron	O
syndrome	O
,	O
characterized	O
by	O
short	BP
stature-17	IP
,	O
specific	O
facial	O
appearance	O
,	O
elevated	O
serum	BG
growth	IG
hormone-26	IG
levels	O
,	O
and	O
decreased	O
insulin	BG
-	IG
like	IG
growth	IG
factor	IG
I-36	IG
levels	O
.	O

PS2713	O
Mutations	O
of	O
the	O
protocadherin19	BG
gene-5	IG
cause	O
a	O
female	O
-	O
related	O
epilepsy	O
of	O
variable	O
severity	O
,	O
with	O
or	O
without	O
mental	BP
retardation-20	IP
and	O
autistic	O
features	O
.	O

PS2719	O
Genotyping	O
of	O
the	O
phenylalanine	BG
hydroxylase-5	IG
gene	O
offers	O
a	O
new	O
tool	O
for	O
characterizing	O
patients	O
with	O
phenylketonuria-15	BP
,	O
refining	O
the	O
diagnosis	O
and	O
aiding	O
in	O
the	O
prediction	O
of	O
the	O
clinical	O
outcome	O
and	O
in	O
the	O
implementation	O
of	O
a	O
more	O
adequate	O
treatment	O
.	O

PS2724	O
Dominant	O
mutations	O
in	O
the	O
skeletal	BG
muscle	IG
ryanodine	IG
receptor-8	IG
(	O
RYR1-10	BG
)	O
gene	O
are	O
well	O
-	O
recognized	O
causes	O
of	O
both	O
malignant	BP
hyperthermia-21	IP
susceptibility	O
and	O
central	O
core	O
disease	O
.	O

PS2732	O
Monosomy	O
3	O
in	O
uveal	BP
melanoma-5	IP
is	O
associated	O
with	O
the	O
presence	O
of	O
an	O
inflammatory	O
phenotype	O
,	O
consisting	O
of	O
a	O
high	O
HLA	BG
class	IG
I	IG
and	IG
II-24	IG
expression	O
as	O
well	O
as	O
an	O
increased	O
number	O
of	O
tumor	O
-	O
infiltrating	O
macrophages	O
.	O

PS2741	O
Familial	O
Mediterranean	O
fever-3	BP
is	O
an	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
mutations	O
in	O
MEFV	BG
gene-14	IG
,	O
which	O
encodes	O
pyrin	O
.	O

PS2753	O
Distribution	O
of	O
tumour	BG
necrosis	IG
factor	IG
-	IG
alpha-7	IG
genotypes	O
in	O
Rheumatoid	BP
arthritis-11	IP
patients	O
did	O
not	O
differ	O
from	O
that	O
in	O
control	O
subjects	O
.	O

PS2755	O
Baculoviral	BG
IAP	IG
repeat	IG
containing	IG
5-5	IG
(	O
also	O
known	O
as	O
survivin-10	BG
)	O
is	O
an	O
important	O
anti	O
-	O
apoptotic	O
protein	O
that	O
has	O
been	O
implicated	O
in	O
many	O
cancer-25	BP
types	O
,	O
and	O
recent	O
studies	O
provide	O
evidence	O
for	O
its	O
role	O
in	O
controlling	O
inflammatory	O
disorders	O
as	O
well	O
.	O

PS2773	O
ROCK-1	BG
collates	O
data	O
from	O
a	O
wealth	O
of	O
breast	BP
cancer-9	IP
molecular	O
profiling	O
and	O
functional	O
screening	O
studies	O
into	O
a	O
single	O
portal	O
,	O
where	O
analysed	O
and	O
annotated	O
results	O
can	O
be	O
accessed	O
at	O
the	O
level	O
of	O
a	O
gene	O
,	O
sample	O
or	O
study	O
.	O

PS2783	O
Because	O
of	O
important	O
roles	O
of	O
cytochromes	BG
P450-7	IG
in	O
the	O
metabolic	O
activation	O
of	O
many	O
precarcinogens	O
,	O
extensive	O
research	O
in	O
the	O
past	O
has	O
focused	O
on	O
the	O
relationship	O
between	O
the	O
distribution	O
of	O
polymorphic	O
variants	O
of	O
different	O
isozymes	O
of	O
P450-36	BG
and	O
cancer-38	BP
susceptibility	O
.	O

PS2785	O
CYP2D6-1	BG
phenotype	O
and	O
genotype	O
have	O
mainly	O
been	O
related	O
to	O
the	O
incidence	O
of	O
lung	O
cancer-14	BP
,	O
but	O
results	O
from	O
13	O
different	O
studies	O
now	O
show	O
an	O
absence	O
of	O
any	O
significant	O
correlation	O
between	O
these	O
parameters	O
.	O

PS2794	O
Seventy	O
-	O
five	O
Congenital	O
muscular	BP
dystrophies-6	IP
patients	O
were	O
tested	O
for	O
laminin	BG
alpha2-12	IG
expression	O
by	O
immunofluorescence	O
and	O
immunoblot	O
.	O

PS2803	O
Apelin-1	BG
,	O
which	O
is	O
a	O
newly	O
identified	O
adipokine	O
,	O
is	O
related	O
to	O
obesity-13	BP
and	O
insulin	BG
resistance-16	IP
.	O

PS2814	O
Comparison	O
of	O
the	O
haplotypes	O
of	O
the	O
PKD1	BG
families-8	IG
indicates	O
that	O
nine	O
different	O
mutations	O
cause	O
Autosomal	O
dominand	O
polycystic	BP
kidney-18	IP
disease1	O
in	O
Iceland	O
,	O
including	O
one	O
de	O
novo	O
mutation	O
.	O

PS2819	O
We	O
identified	O
five	O
distinct	O
mutations	O
responsible	O
for	O
transforming	BG
growth	IG
factor	IG
beta-11	IG
induced	O
corneal	BP
dystrophies-14	IP
(	O
R124R	O
,	O
R124H	O
,	O
R555W	O
,	O
R555Q	O
,	O
and	O
H626R	O
)	O
.	O

PS2824	O
Taken	O
together	O
,	O
most	O
missense	O
and	O
in	O
-	O
frame	O
Multiple	O
Endocrine	O
Neoplasia-12	BP
type	O
1	O
genomic	O
alterations	O
affect	O
one	O
or	O
all	O
domains	O
of	O
menin-23	BG
interacting	O
with	O
JunD-26	BG
[	O
codons	O
1	O
-	O
40	O
;	O
139	O
-	O
242	O
;	O
323	O
-	O
428	O
]	O
,	O
Smad3-42	BG
[	O
distal	O
to	O
codon	O
478	O
]	O
,	O
and	O
NFkappaB-51	BG
[	O
codons	O
276	O
-	O
479	O
]	O
,	O
three	O
major	O
effectors	O
in	O
transcription	O
and	O
cell	O
growth	O
regulation	O
.	O

PS2826	O
Even	O
though	O
carnitine	BG
palmitoyltransferase	IG
1A	IG
deficiency-6	IP
may	O
be	O
life	O
-	O
threatening	O
and	O
lead	O
to	O
prolonged	O
coma-16	BP
,	O
the	O
long	O
-	O
term	O
prognosis	O
is	O
good	O
.	O

PS2838	O
c	BG
-	IG
erbB2-3	IG
overexpression	O
and	O
p21-6	BG
(	O
waf-8	BG
)	O
loss	O
were	O
higher	O
in	O
MNT	O
than	O
in	O
hepatocellular	BP
carcinoma-18	IP
patients	O
,	O
however	O
,	O
this	O
did	O
not	O
reach	O
a	O
statistically	O
significant	O
level	O
.	O

PS2841	O
Our	O
data	O
suggest	O
that	O
SIX3-5	BG
mutations	O
result	O
in	O
relatively	O
severe	O
Holoprosencephaly-11	BP
and	O
that	O
there	O
is	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
as	O
shown	O
by	O
functional	O
studies	O
using	O
animal	O
models	O
.	O

PS2868	O
Furthermore	O
,	O
an	O
overall	O
reduced	O
amount	O
of	O
HLA	BG
class	IG
I	IG
gene-11	IG
transcription	O
was	O
observed	O
in	O
melanoma-16	BP
metastases	O
during	O
disease	O
progression	O
in	O
three	O
individuals	O
.	O

PS2871	O
Phenylketonuria-1	BP
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
phenylalanine	BG
hydroxylase-11	IG
enzyme	O
.	O

PS2886	O
Myotonic	BP
dystrophy-2	IP
is	O
a	O
multisystemic	O
disease	O
caused	O
by	O
the	O
expansion	O
of	O
a	O
CTG	O
repeat	O
,	O
located	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
DMPK	BG
gene-27	IG
.	O

PS2892	O
The	O
myelin	BG
protein	IG
zero	IG
lys236del	IG
mutation-6	IG
is	O
associated	O
with	O
an	O
autosomal	O
dominant	O
,	O
adult	O
onset	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
phenotype	O
,	O
with	O
variable	O
penetrance	O
ranging	O
from	O
an	O
asymptomatic	O
state	O
to	O
foot	O
deformities	O
,	O
pedal	BP
numbness-37	IP
,	O
and	O
muscle	BP
cramps-41	IP
.	O

PS2893	O
The	O
Polycomb	O
group	O
genes	O
,	O
including	O
Bmi1-7	BG
and	O
Mel	BG
-	IG
18-11	IG
,	O
have	O
been	O
implicated	O
in	O
the	O
maintenance	O
of	O
hematopoietic	O
stem	O
cells	O
and	O
suggested	O
to	O
be	O
oncogenic	O
and	O
tumor	O
suppressive	O
,	O
respectively	O
,	O
in	O
breast	BP
cancer-36	IP
.	O

PS2915	O
Fragile	O
X	O
syndrome	O
is	O
a	O
neurodevelopmental	O
disorder	O
that	O
is	O
caused	O
by	O
large	O
methylated	O
expansions	O
of	O
a	O
CGG	O
repeat	O
(	O
>	O
200	O
)	O
region	O
upstream	O
of	O
the	O
FMR1	BG
gene-28	IG
that	O
results	O
in	O
the	O
lack	O
of	O
expression	O
of	O
the	O
fragile	O
X	O
mental	BP
retardation-41	IP
protein	O
.	O

PS2928	O
Promoter	O
methylation	O
of	O
the	O
deoxyribonucleic	O
acid	O
repair	O
gene	O
,	O
O	BG
(	IG
6	IG
)	IG
-	IG
methylguanine	IG
-	IG
deoxyribonucleic	IG
acid	IG
methyltransferase-19	IG
(	O
O	BG
(	IG
6	IG
)	IG
-	IG
methylguanine	IG
-	IG
DNA	IG
methyltransferase-29	IG
)	O
,	O
is	O
associated	O
with	O
improved	O
outcome	O
of	O
patients	O
with	O
glioblastoma-40	BP
multiforme	O
and	O
anaplastic	O
astrocytoma-44	BP
treated	O
with	O
temozolomide	O
.	O

PS2930	O
Although	O
not	O
sufficient	O
by	O
itself	O
to	O
rescue	O
mutant	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
therapeutically	O
,	O
the	O
elevation	O
of	O
ubiquitin	BG
C	IG
-	IG
terminal	IG
hydrolase	IG
-	IG
L1-25	IG
and	O
its	O
effect	O
on	O
cystic	BG
fibrosis	IG
transmembrane	IG
conductance	IG
regulator-34	IG
processing	O
provides	O
insight	O
into	O
its	O
potential	O
roles	O
in	O
cystic	BP
fibrosis-44	IP
and	O
other	O
diseases	O
.	O

PS2936	O
Recent	O
studies	O
have	O
suggested	O
that	O
some	O
of	O
the	O
phenotypic	O
features	O
of	O
Familial	BP
adenomatous	IP
polyposis-14	IP
are	O
dependent	O
on	O
the	O
position	O
of	O
the	O
mutation	O
within	O
the	O
APC	BG
gene-26	IG
.	O

PS2946	O
To	O
investigate	O
the	O
macrophage	O
migration	O
inhibitory	O
factor	O
expression	O
and	O
-	O
173	O
G	O
/	O
C	O
polymorphism	O
of	O
the	O
migration	BG
inhibitory	IG
factor	IG
gene-21	IG
in	O
nonalcoholic	O
fatty	BP
liver-25	IP
disease	O
.	O

PS2950	O
These	O
data	O
will	O
be	O
useful	O
in	O
evaluating	O
habilitation	O
options	O
for	O
people	O
with	O
GJB2-13	BG
related	O
deafness-15	BP
.	O

PS2956	O
When	O
we	O
assumed	O
that	O
disease	O
susceptibility	O
was	O
inherited	O
as	O
a	O
recessive	O
phenotype	O
,	O
we	O
found	O
that	O
the	O
rs11614913	BG
SNP-19	IG
in	O
hsa	BG
-	IG
mir	IG
-	IG
196a2-25	IG
was	O
associated	O
with	O
survival	O
in	O
individuals	O
with	O
non	O
-	O
small	O
cell	O
lung	O
cancer-38	BP
.	O

PS2958	O
Further	O
characterization	O
of	O
miRNA	BG
SNPs-5	IG
may	O
open	O
new	O
avenues	O
for	O
the	O
study	O
of	O
cancer-14	BP
and	O
therapeutic	O
interventions	O
.	O

PS2964	O
The	O
RHO	BG
C110Y	IG
mutation-4	IG
has	O
been	O
recently	O
reported	O
to	O
cause	O
a	O
phenotypically	O
unspecified	O
form	O
of	O
autosomal	O
dominant	O
retinitis	BP
pigmentosa-19	IP
.	O

PS2966	O
Mucopolysaccharidosis-1	BP
type	O
I	O
is	O
an	O
autosomal	O
recessive	O
lysosomal	O
storage	O
disorder	O
caused	O
by	O
a	O
deficiency	O
of	O
alpha	BG
-	IG
L	IG
-	IG
iduronidase-20	IG
.	O

PS2968	O
Polymerase	O
chain	O
reaction	O
of	O
genomic	O
DNA	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
was	O
used	O
to	O
determine	O
genotypes	O
of	O
the	O
control	O
subjectsLA	BG
-	IG
4	IG
exon	IG
1-24	IG
(	O
+	O
49	O
)	O
and	O
promoter	O
(	O
-	O
318	O
)	O
in	O
80	O
systemic	BP
lupus	IP
erythematosus-39	IP
patients	O
and	O
86	O
healthy	O
control	O
subjects	O
.	O

PS2998	O
CYP2D6-1	BG
,	O
was	O
determined	O
genotypically	O
for	O
122	O
healthy	O
controls	O
and	O
106	O
lung	O
cancer-13	BP
patients	O
using	O
Xba	O
I	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
,	O
together	O
with	O
a	O
combination	O
of	O
two	O
recently	O
published	O
polymerase	O
chain	O
reaction	O
based	O
approaches	O
.	O

PS3005	O
Genotype	O
-	O
phenotype	O
correlations	O
in	O
cystic	BP
fibrosis-7	IP
may	O
be	O
difficult	O
to	O
establish	O
because	O
of	O
phenotype	O
variability	O
,	O
which	O
is	O
associated	O
with	O
certain	O
cystic	BG
fibrosis	IG
transmembrane	IG
conductance	IG
regulator-27	IG
gene	O
mutations	O
and	O
the	O
existence	O
of	O
complex	O
alleles	O
.	O

PS3017	O
Mucopolysaccharidosis-1	BP
type	O
II	O
(	O
Hunter	O
disease	O
)	O
is	O
an	O
X	O
-	O
linked	O
disorder	O
due	O
to	O
deficiency	O
of	O
the	O
lysosomal	BG
enzyme	IG
iduronate	IG
2	IG
-	IG
sulphatase-24	IG
.	O

PS3024	O
Associations	O
between	O
attention	BP
deficit	IP
hyperactivity	IP
disorder-6	IP
and	O
genetic	O
polymorphisms	O
in	O
the	O
dopamine	BG
receptors-13	IG
,	O
transporter	O
and	O
metabolizing	O
enzymes	O
have	O
been	O
reported	O
in	O
different	O
ethnic	O
groups	O
.	O

PS3028	O
Mucopolysaccharidosis-1	BP
type	O
I	O
is	O
an	O
autosomal	O
recessive	O
disease	O
caused	O
by	O
mutations	O
in	O
the	O
alpha	BG
-	IG
L	IG
-	IG
iduronidase-18	IG
gene	O
.	O

PS3030	O
Congenital	BP
central	IP
hypoventilation-3	IP
syndrome	O
is	O
caused	O
by	O
mutations	O
in	O
PHOX2B-10	BG
,	O
which	O
is	O
essential	O
for	O
maturation	O
of	O
the	O
neural	O
crest	O
into	O
the	O
autonomic	O
nervous	O
system	O
and	O
is	O
expressed	O
in	O
the	O
dorsal	O
rhombencephalon	O
,	O
a	O
region	O
that	O
gives	O
rise	O
to	O
facial	O
structures	O
.	O

PS3039	O
In	O
conclusion	O
,	O
other	O
factors	O
than	O
phenotypes	O
and	O
genotypes	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
apo-18	BG
(	O
a	O
)	O
may	O
be	O
responsible	O
for	O
the	O
elevation	O
of	O
serum	BG
Lp-30	IG
(	O
a	O
)	O
in	O
diabetic	O
patients	O
with	O
retinopathy-38	BP
.	O

PS3042	O
In	O
all	O
six	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
2a	IG
families-9	IG
expressing	O
Hirschsprung	BP
'	IP
s	IP
disease-14	IP
,	O
the	O
RET	BG
mutation-18	IG
predisposing	O
to	O
the	O
combined	O
phenotype	O
occurred	O
in	O
exon	O
10	O
at	O
codons	O
609	O
(	O
n	O
=	O
2	O
)	O
,	O
618	O
(	O
n	O
=	O
3	O
)	O
,	O
or	O
620	O
(	O
n	O
=	O
1	O
)	O
.	O

PS3043	O
The	O
T8993G-2	BG
mutation	O
in	O
the	O
mitochondrial	O
genome	O
was	O
found	O
in	O
several	O
maternal	O
members	O
of	O
six	O
pedigrees	O
,	O
whose	O
clinical	O
status	O
ranged	O
from	O
no	O
symptoms	O
to	O
severe	O
infantile	O
subacute	O
necrotising	O
encephalomyelopathy-30	BP
(	O
Leigh	O
'	O
s	O
disease	O
)	O
.	O

PS3057	O
Friedreich	O
'	O
s	O
ataxia-4	BP
,	O
an	O
autosomal	O
recessive	O
neurodegenerative	O
disorder	O
,	O
is	O
in	O
most	O
cases	O
due	O
to	O
a	O
homozygous	O
intronic	O
expansion	O
resulting	O
in	O
the	O
loss	O
of	O
function	O
of	O
frataxin-29	BG
.	O

PS3069	O
Dyschromatosis-1	BP
symmetrica	O
hereditaria	O
is	O
a	O
rare	O
autosomal	O
dominant	O
cutaneous	O
disorder	O
characterized	O
by	O
a	O
mixture	O
of	O
hyperpigmented	O
and	O
hypopigmented	O
macules	O
of	O
various	O
sizes	O
on	O
the	O
extremities	O
and	O
caused	O
by	O
the	O
mutations	O
of	O
adenosine	BG
deaminase-33	IG
acting	O
on	O
RNA1-36	BG
gene	O
.	O

PS3071	O
The	O
isolation	O
of	O
the	O
37LRP-5	BG
/	O
p40-7	BG
gene	O
is	O
a	O
prerequisite	O
for	O
identifying	O
the	O
molecular	O
mechanisms	O
responsible	O
for	O
the	O
constant	O
up	O
-	O
regulation	O
of	O
the	O
67	O
-	O
kD	O
laminin	BG
receptor-30	IG
expression	O
in	O
cancer-33	BP
cells	O
.	O

PS3073	O
Six	O
ABCB1-2	BG
single	O
nucleotide	O
polymorphisms	O
were	O
determined	O
in	O
90	O
Czech	O
breast	BP
cancer-12	IP
patients	O
by	O
a	O
novel	O
method	O
that	O
allows	O
simultaneous	O
assessment	O
of	O
multiple	O
polymorphisms	O
on	O
a	O
single	O
electronic	O
microarray	O
.	O

PS3074	O
Expression	O
levels	O
of	O
ABCB1-4	BG
were	O
quantified	O
in	O
tumor	O
and	O
nontumor	O
samples	O
of	O
breast	BP
cancer-14	IP
patients	O
by	O
real	O
-	O
time	O
PCR	O
.	O

PS3076	O
These	O
data	O
suggest	O
that	O
,	O
in	O
combination	O
with	O
meat	O
intake	O
,	O
some	O
proportion	O
of	O
the	O
international	O
variability	O
in	O
colorectal	BP
cancer-20	IP
incidence	O
may	O
be	O
attributable	O
to	O
genetic	O
susceptibility	O
to	O
heterocyclic	O
amines	O
,	O
as	O
determined	O
by	O
NAT2	BG
genotype-36	IG
.	O

PS3084	O
Mutations	O
in	O
the	O
cardiac	BG
myosin	IG
-	IG
binding	IG
protein	IG
C	IG
gene-10	IG
(	O
MYBPC3-12	BG
)	O
are	O
responsible	O
for	O
up	O
to	O
50	O
%	O
of	O
familial	O
cases	O
with	O
hypertrophic	BP
cardiomyopathy-26	IP
.	O

PS3092	O
And	O
palmoplantar	BP
keratoderma-3	IP
can	O
be	O
an	O
accompanied	O
symptom	O
caused	O
by	O
either	O
keratin	BG
1-13	IG
or	O
keratin	O
10	O
mutation	O
.	O

PS3096	O
Angiotensin	BG
-	IG
converting	IG
enzyme-4	IG
activity	O
and	O
polymorphism	O
contribute	O
significantly	O
to	O
the	O
prognosis	O
of	O
patients	O
with	O
cardiomyopathy-16	BP
.	O

PS3101	O
We	O
conclude	O
that	O
cardiovascular	BP
malformations-5	IP
,	O
coloboma-7	BP
,	O
and	O
facial	O
asymmetry	O
are	O
common	O
findings	O
in	O
CHARGE	O
syndrome	O
caused	O
by	O
CHD7-20	BG
mutation	O
.	O

PS3119	O
In	O
addition	O
to	O
macrothrombocytopenia-4	BP
,	O
an	O
abnormal	O
distribution	O
of	O
nonmuscle	BG
myosin	IG
heavy	IG
chain	IG
IIA-14	IG
within	O
leukocytes	O
was	O
observed	O
in	O
all	O
individuals	O
,	O
including	O
those	O
without	O
Dohle	O
-	O
like	O
bodies	O
.	O

PS3123	O
Early	O
onset	O
ataxia-3	BP
with	O
ocular	O
motor	O
apraxia	O
and	O
hypoalbuminaemia-9	BP
/	O
ataxia	O
-	O
oculomotor	O
apraxia-14	BP
1	O
is	O
a	O
recessively	O
inherited	O
ataxia-20	BP
caused	O
by	O
mutations	O
in	O
the	O
aprataxin	BG
gene-27	IG
.	O

PS3128	O
Mutations	O
of	O
GJB2-3	BG
(	O
encoding	O
connexin	BG
26-7	IG
)	O
are	O
the	O
most	O
common	O
cause	O
of	O
hearing	BP
loss-16	IP
in	O
different	O
populations	O
,	O
and	O
a	O
broad	O
spectrum	O
of	O
GJB2-26	BG
mutations	O
has	O
been	O
identified	O
.	O

PS3131	O
Mutations	O
of	O
GJB2-3	BG
(	O
encoding	O
connexin	BG
26-7	IG
)	O
are	O
the	O
most	O
common	O
cause	O
of	O
hearing	BP
loss-16	IP
in	O
different	O
populations	O
,	O
and	O
a	O
broad	O
spectrum	O
of	O
GJB2-26	BG
mutations	O
has	O
been	O
identified	O
.	O

PS3139	O
This	O
study	O
describes	O
the	O
phenotype	O
of	O
2	O
Belgian	O
families	O
with	O
sensorineural	BP
hearing	IP
loss-13	IP
linked	O
to	O
DFNA22-16	BG
,	O
both	O
with	O
a	O
pathogenic	O
change	O
in	O
the	O
deafness	O
gene	BG
MYO6-27	IG
.	O

PS3140	O
Mutations	O
in	O
the	O
CLCN7	BG
gene-5	IG
are	O
responsible	O
not	O
only	O
for	O
a	O
substantial	O
portion	O
of	O
autosomal	O
recessive	O
osteopetrosis-17	BP
patients	O
but	O
also	O
for	O
other	O
forms	O
of	O
osteopetrosis-25	BP
characterized	O
by	O
different	O
severity	O
and	O
inheritance	O
.	O

PS3149	O
Mean	O
first	O
-	O
phase	O
insulin-5	BG
response	O
was	O
higher	O
in	O
subjects	O
with	O
normal	O
glucose	O
tolerance	O
compared	O
with	O
subjects	O
with	O
impaired	BP
glucose	IP
tolerance-21	IP
and	O
subjects	O
diagnosed	O
by	O
2	O
-	O
h	O
oral	O
glucose	O
tolerance	O
tests	O
criteria	O
alone	O
.	O

PS3153	O
From	O
the	O
three	O
different	O
human	BG
Uncoupling	IG
proteins-7	IG
identified	O
so	O
far	O
by	O
gene	O
cloning	O
both	O
UCP2-15	BG
and	O
UCP3-17	BG
were	O
mapped	O
in	O
close	O
proximity	O
(	O
75	O
-	O
150	O
kb	O
)	O
to	O
regions	O
of	O
human	O
chromosome	O
11	O
(	O
11q13	O
)	O
that	O
have	O
been	O
linked	O
to	O
obesity-43	BP
and	O
hyperinsulinaemia-45	BP
.	O

PS3163	O
Mutations	O
in	O
the	O
MYBPC3	BG
gene-5	IG
are	O
one	O
of	O
the	O
most	O
frequent	O
genetic	O
causes	O
of	O
Hypertrophic	BP
cardiomyopathy-16	IP
.	O

PS3174	O
GM2	O
gangliosidosis	O
variant	O
0	O
(	O
Sandhoff	O
disease	O
,	O
SD	O
)	O
is	O
a	O
fatal	O
,	O
progressive	O
neurodegenerative	O
lysosomal	BP
storage	IP
disease-19	IP
caused	O
by	O
mutations	O
in	O
the	O
HEXB	BG
gene-26	IG
.	O

PS3182	O
To	O
investigate	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
Chinese	O
patients	O
with	O
retinitis	BP
pigmentosa-13	IP
caused	O
by	O
rhodopsin	BG
gene-17	IG
mutation	O
.	O

PS3189	O
The	O
importance	O
of	O
correct	O
control	O
of	O
eIF2-7	BG
and	O
eIF2B-9	BG
for	O
normal	O
physiology	O
is	O
underlined	O
by	O
the	O
recent	O
involvement	O
of	O
the	O
five	O
genes	O
that	O
encode	O
the	O
five	O
eIF2B	BG
subunits-28	IG
in	O
a	O
severe	O
autosomal	O
recessive	O
neurodegenerative	O
disease	O
,	O
described	O
in	O
young	O
children	O
as	O
CACH	O
(	O
childhood	O
ataxia-45	BP
with	O
central	O
nervous	O
system	O
hypomyelination	O
)	O
/	O
VWM-53	BG
(	O
leukoencephalopathy-55	BP
with	O
vanishing	O
white	O
matter	O
)	O
syndrome	O
.	O

PS3192	O
Here	O
,	O
we	O
show	O
that	O
the	O
gene	O
encoding	O
p44-9	BG
,	O
a	O
subunit	O
of	O
the	O
basal	BG
transcription	IG
factor	IG
TFIIH-18	IG
,	O
is	O
duplicated	O
in	O
the	O
spinal	BP
muscular	IP
atrophy-26	IP
region	O
and	O
that	O
the	O
p44	BG
gene	IG
products-33	IG
(	O
p44t	O
and	O
p44c	O
)	O
differ	O
by	O
three	O
amino	O
acid	O
changes	O
.	O

PS3208	O
Basic	O
criteria	O
for	O
Wolfram	O
Syndrome	O
clinical	O
diagnosis	O
were	O
coexistence	O
of	O
insulin	BG
-	IP
treated	IP
diabetes	IP
mellitus-15	IP
and	O
optic	BP
atrophy-18	IP
occurring	O
before	O
15	O
years	O
of	O
age	O
.	O

PS3209	O
Mutations	O
in	O
the	O
gene	O
encoding	O
lysosomal	BG
protective	IG
protein-8	IG
/	O
cathepsin	BG
A-11	IG
are	O
the	O
cause	O
of	O
the	O
lysosomal	O
disorder	O
galactosialidosis-19	BP
.	O

PS3213	O
Genotype	O
-	O
phenotype	O
correlations	O
highlighted	O
the	O
function	O
of	O
ABCA4-9	BG
in	O
retinitis	BP
pigmentosa-12	IP
,	O
cone	O
-	O
rod	O
dystrophy	O
and	O
Stargardt	O
/	O
Fundus	O
Flavimaculatus	O
disease	O
.	O

PS3215	O
Genotype	O
-	O
phenotype	O
correlations	O
highlighted	O
the	O
function	O
of	O
ABCA4-9	BG
in	O
retinitis	BP
pigmentosa-12	IP
cone	O
-	O
rod	O
dystrophy	O
and	O
Stargardt	O
/	O
Fundus	O
Flavimaculatus	O
disease	O
.	O

PS3223	O
In	O
1990	O
,	O
the	O
molecular	O
underpinnings	O
of	O
hypertrophic	BP
cardiomyopathy-9	IP
were	O
exposed	O
with	O
the	O
identification	O
of	O
a	O
mutation	O
in	O
the	O
MYH7	BG
-	IG
encoded	IG
beta	IG
myosin	IG
heavy	IG
chain-26	IG
.	O

PS3226	O
Familial	O
hemiplegic	O
migraine	O
,	O
episodic	BP
ataxia-6	IP
type	O
2	O
,	O
and	O
spinocerebellar	BP
ataxia-12	IP
type	O
6	O
are	O
allelic	O
disorders	O
of	O
the	O
CACNA1A	BG
gene-21	IG
(	O
coding	O
for	O
the	O
alpha	O
(	O
1A	O
)	O
subunit	O
of	O
P	O
/	O
Q	O
calcium	O
channels	O
)	O
,	O
usually	O
associated	O
with	O
different	O
types	O
of	O
mutations	O
(	O
missense	O
,	O
protein	O
truncating	O
,	O
and	O
expansion	O
,	O
respectively	O
)	O
.	O

PS3244	O
Neurofibromatosis-1	BP
type	O
1	O
and	O
its	O
related	O
disorders	O
(	O
Neurofibromatosis	O
type	O
1	O
-	O
Noonan	O
syndrome	O
and	O
Watson	O
syndrome	O
)	O
are	O
caused	O
by	O
heterozygous	O
mutations	O
in	O
the	O
Neurofibromatosis	BG
type	IG
1	IG
gene-29	IG
.	O

PS3255	O
Hepatic	O
CPT	BG
I-3	IG
deficiency	O
is	O
characterized	O
by	O
recurrent	O
episodes	O
of	O
Reye	O
-	O
like	O
syndrome	O
,	O
whereas	O
severe	O
muscular	O
and	O
cardiac	O
signs	O
are	O
associated	O
with	O
episodes	O
of	O
fasting	O
hypoglycaemia-28	BP
in	O
defects	O
of	O
carnitine	O
transport	O
and	O
translocase-35	BG
.	O

PS3257	O
Mutations	O
in	O
the	O
gap	BG
junction	IG
protein	IG
connexin	IG
26-8	IG
gene	O
(	O
GJB2-11	BG
)	O
seem	O
to	O
account	O
for	O
many	O
cases	O
of	O
congenital	BP
sensorineural	IP
hearing-22	IP
impairment	O
,	O
the	O
reported	O
prevalence	O
being	O
34	O
-	O
50	O
%	O
in	O
autosomal	O
recessive	O
cases	O
and	O
10	O
-	O
37	O
%	O
in	O
sporadic	O
cases	O
.	O

PS3263	O
Glutaric	O
aciduria-2	BP
type	O
1	O
is	O
an	O
autosomal	O
recessive	O
neurometabolic	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
glutaryl	BG
-	IG
CoA	IG
dehydrogenase	IG
gene-20	IG
,	O
leading	O
to	O
an	O
accumulation	O
and	O
high	O
excretion	O
of	O
glutaric	O
acid	O
and	O
3	O
-	O
hydroxyglutaric	O
acid	O
.	O

PS3286	O
Screening	O
for	O
sequence	O
variants	O
in	O
the	O
glucokinase	BG
gene-8	IG
was	O
performed	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
and	O
direct	O
sequencing	O
in	O
132	O
children	O
with	O
maturity	O
onset	O
diabetes	O
of	O
the	O
young	O
and	O
in	O
9	O
children	O
with	O
chronic	O
fasting	O
hyperglycaemia-36	BP
but	O
without	O
laboratory	O
evidence	O
for	O
Type	BG
I-43	IG
(	O
insulin-45	BG
-	O
dependent	O
)	O
diabetes	BP
mellitus-50	IP
and	O
with	O
normoglycaemic	O
parents	O
(	O
"	O
non	O
-	O
classical	O
"	O
maturity	O
onset	O
diabetes	O
of	O
the	O
young	O
)	O
.	O

PS3292	O
Cystic	BP
fibrosis-2	IP
is	O
caused	O
by	O
mutations	O
in	O
the	O
Cystic	BG
fibrosis	IG
transmembrane	IG
conductance	IG
regulator-13	IG
gene	O
,	O
which	O
encodes	O
a	O
protein	O
expressed	O
in	O
the	O
apical	O
membrane	O
of	O
exocrine	O
epithelial	O
cells	O
.	O

PS3295	O
Screening	O
mutations	O
in	O
the	O
MYH7	BG
gene-6	IG
should	O
be	O
viewed	O
as	O
a	O
reasonable	O
procedure	O
in	O
obstructive	O
hypertrophic	BP
cardiomyopathy-17	IP
patients	O
.	O

PS3299	O
In	O
Alstrom	O
syndrome	O
,	O
severe	O
childhood	O
obesity-7	BP
,	O
waist	O
circumference	O
,	O
and	O
body	O
fat	O
decrease	O
with	O
age	O
,	O
whereas	O
insulin	BG
resistance-21	IP
increases	O
.	O

PS3302	O
Virological	BP
failure-2	IP
during	O
combination	O
therapy	O
can	O
be	O
due	O
to	O
resistance	O
to	O
either	O
treatment	O
drug	O
,	O
emphasising	O
the	O
need	O
to	O
change	O
both	O
the	O
reverse	BG
transcriptase-24	IG
inhibitor	O
and	O
the	O
protease	O
inhibitor	O
.	O

PS3311	O
The	O
degree	O
of	O
in	O
vitro	O
pharmacological	O
muscle	O
contracture	O
response	O
and	O
the	O
baseline	O
serum	BG
creatine	IG
kinase-15	IG
concentration	O
were	O
used	O
to	O
generate	O
a	O
series	O
of	O
quantitative	O
phenotypes	O
for	O
Malignant	BP
hyperthermia-28	IP
.	O

PS3324	O
Unilateral	O
motor	O
seizures-3	BP
may	O
be	O
a	O
specific	O
clinical	O
characteristic	O
of	O
severe	O
myoclonic	O
epilepsy	O
in	O
infancy	O
caused	O
by	O
SCN1A-18	BG
mutations	O
.	O

PS3334	O
Pachyonychia	BP
congenita-2	IP
is	O
a	O
rare	O
,	O
autosomal	O
dominant	O
keratin	O
disorder	O
caused	O
by	O
mutations	O
in	O
four	O
genes	O
(	O
KRT6A-18	BG
,	O
KRT6B-20	BG
,	O
KRT16-22	BG
,	O
or	O
KRT17-25	BG
)	O
.	O

PS3341	O
All	O
but	O
5	O
of	O
the	O
56	O
index	O
patients	O
with	O
X	O
-	O
linked	O
agammaglobulinemia-13	BP
screened	O
with	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
analysis	O
showed	O
Bruton	O
'	O
s	O
tyrosine	BG
kinase	IG
gene-28	IG
abnormalities	O
,	O
and	O
in	O
2	O
of	O
the	O
5	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
-	O
negative	O
patients	O
,	O
no	O
Bruton	O
'	O
s	O
tyrosine	BG
kinase	IG
protein-52	IG
was	O
found	O
by	O
Western	O
blot	O
analysis	O
.	O

PS3348	O
Further	O
study	O
of	O
those	O
with	O
a	O
family	O
history	O
of	O
HAND2	BG
mutations-11	IG
will	O
help	O
convincingly	O
relate	O
their	O
genotype	O
to	O
the	O
pathogenesis	O
of	O
congenial	BP
heart	IP
disease-24	IP
.	O

PS3365	O
On	O
the	O
contrary	O
,	O
a	O
statistically	O
significant	O
association	O
was	O
found	O
between	O
renal	BP
adenocarcinoma-13	IP
and	O
C3F-15	BG
and	O
group	BG
-	IG
specific	IG
component2	IG
genes-21	IG
.	O

PS3378	O
Polymorphisms	O
in	O
the	O
3	O
'	O
-	O
and	O
the	O
5	O
'	O
-	O
UTR	O
of	O
the	O
TS	BG
gene-16	IG
were	O
determined	O
by	O
a	O
PCR	O
assay	O
in	O
53	O
colorectal	BP
cancer-26	IP
tissues	O
.	O

M18	O
physiological	O
ifn	BG
-	IG
gamma-4	IG
response	O
in	O
sw480	O
colon	BP
carcinoma-9	IP
cells	O
was	O
resistant	O
to	O
inhibition	O
with	O
1	O
m	O
gf	O
109203x	O
and	O
was	O
suppressed	O
only	O
when	O
staurosporine	O
concentration	O
was	O
increased	O
to	O
1	O
m	O
.	O

M23	O
thus	O
,	O
histone	BG
deacetylase-4	IG
inhibitors	O
butyrate	O
and	O
trichostatin	O
a	O
can	O
rescue	O
major	O
histocompatibility	O
complex	O
class	O
ii	O
-	O
inducibility	O
in	O
bladder	BP
carcinoma-21	IP
cellsand	O
restore	O
constitutive	O
major	O
histocompatibility	O
complex	O
class	O
ii	O
expression	O
in	O
plasmacytoma-32	BP
cells	O
.	O

M26	O
a	O
potentiating	O
effect	O
of	O
phorbol	O
myristate	O
acetate	O
has	O
been	O
reported	O
in	O
thyroid	BP
carcinoma-13	IP
cellsbut	O
,	O
in	O
contrast	O
to	O
ls1034	O
cells	O
,	O
normal	O
ifn	BG
-	IG
gamma-25	IG
response	O
in	O
those	O
cells	O
was	O
only	O
partially	O
lost	O
as	O
a	O
result	O
of	O
malignant	BP
transformation-39	IP
.	O

M44	O
thus	O
,	O
bmp4-3	BG
is	O
a	O
strong	O
candidate	O
to	O
contribute	O
to	O
axenfeld	O
-	O
rieger	O
anomaly	O
and	O
other	O
developmental	O
conditions	O
associated	O
with	O
human	O
glaucoma-22	BP
.	O

M50	O
although	O
elevated	O
intraocular	O
pressure	O
likely	O
results	O
in	O
inner	O
retinal	O
cell	O
death	O
in	O
glaucoma-13	BP
,	O
deficiency	O
of	O
inner	O
retinal	O
cells	O
in	O
bmp4	BG
+	IG
/	IG
-	IG
heterozygotes-25	IG
is	O
at	O
least	O
partly	O
a	O
developmental	O
phenomenon	O
.	O

M55	O
conclusion	O
esr1	BG
gene-3	IG
alleles	O
are	O
unlikely	O
to	O
be	O
a	O
major	O
cause	O
of	O
obesity-13	BP
in	O
women	O
.	O

M59	O
esr2	BG
rs928554-2	IG
and	O
rs4986938-4	BG
,	O
but	O
not	O
rs1256049	O
,	O
have	O
been	O
associated	O
with	O
bulimic	O
behavior	O
[	O
19	O
]	O
and	O
rs1256049	O
,	O
but	O
not	O
rs4986938	O
,	O
with	O
anorexia-27	BP
nervosa	O
[	O
20	O
]	O
.	O

M78	O
this	O
might	O
explain	O
the	O
difference	O
between	O
our	O
results	O
and	O
the	O
association	O
of	O
esr1-13	BG
and	O
male	O
obesity-16	BP
previously	O
reported	O
[	O
14	O
]	O
.	O

M90	O
immunohistochemical	O
analysis	O
of	O
connexin43-4	BG
was	O
performed	O
on	O
testicular	O
biopsies	O
from	O
29	O
patients	O
with	O
azoospermia-14	BP
(	O
n	O
=	O
23	O
)	O
and	O
severe	O
oligospermia-22	BP
(	O
n	O
=	O
6	O
)	O
,	O
who	O
gave	O
informed	O
consent	O
to	O
this	O
experiment	O
.	O

M104	O
however	O
,	O
survivin-3	BG
expression	O
has	O
been	O
detected	O
in	O
various	O
human	O
cancers-11	BP
and	O
correlations	O
have	O
been	O
recognized	O
between	O
the	O
level	O
of	O
expression	O
of	O
this	O
gene	O
in	O
tumors	O
and	O
prognosis	O
.	O

M119	O
based	O
on	O
our	O
in	O
vitro	O
studies	O
,	O
we	O
suggest	O
that	O
overexpression	O
of	O
skp2-13	BG
may	O
be	O
one	O
of	O
the	O
mechanisms	O
that	O
allow	O
prostate	BP
cancer-23	IP
cells	O
to	O
escape	O
growth	O
control	O
mediated	O
by	O
p27-31	BG
.	O

M124	O
many	O
aggressive	O
prostate	BP
cancers-4	IP
display	O
decreased	O
p27	BG
protein-8	IG
levels	O
in	O
the	O
presence	O
of	O
high	O
p27	BG
mrna-16	IG
,	O
suggesting	O
that	O
p27-20	BG
depletion	O
may	O
result	O
from	O
ectopic	O
proteolysis	O
.	O

M126	O
significantly	O
,	O
overexpression	O
of	O
skp2-5	BG
has	O
been	O
observed	O
in	O
many	O
cancer-11	BP
cell	O
linesas	O
well	O
as	O
in	O
primary	O
cancer-18	BP
specimens	O
and	O
many	O
of	O
these	O
tumors	O
also	O
display	O
down	O
-	O
regulation	O
of	O
p27-31	BG
.	O

M133	O
studies	O
on	O
cases	O
of	O
familial	O
amyotrophic	BP
lateral	IP
sclerosis-8	IP
(	O
famyotrophic	BP
lateral	IP
sclerosis-12	IP
)	O
indicate	O
a	O
pathogenesis	O
related	O
to	O
dominantly	O
inherited	O
point	O
-	O
mutations	O
in	O
the	O
gene	O
for	O
cu	O
,	O
zn	O
superoxide	BG
dismutase-32	IG
(	O
sod1-34	BG
)	O
on	O
chromosome	O
21	O
[	O
34	O
,	O
35	O
]	O
.	O

M140	O
tnf-1	BG
,	O
previously	O
known	O
as	O
lymphotoxin	O
and	O
cachetin	O
,	O
is	O
believed	O
to	O
be	O
involved	O
in	O
the	O
wasting	O
that	O
occurs	O
during	O
acute	O
and	O
chronic	O
illness	O
and	O
malignancy-26	BP
.	O

M144	O
leptin-1	BG
serves	O
as	O
a	O
marker	O
of	O
energy	O
sufficiency	O
by	O
rapidly	O
decreasing	O
during	O
starvation	O
and	O
weight	BP
loss-16	IP
.	O

M152	O
levels	O
of	O
plasminogen	BG
activator	IG
inhibitor	IG
type	IG
-	IG
1-8	IG
are	O
elevated	O
in	O
acute	O
conditions	O
such	O
as	O
deep	BP
venous	IP
thrombosis-18	IP
,	O
and	O
chronic	O
conditions	O
such	O
as	O
obesity-25	BP
,	O
the	O
metabolic	O
syndrome	O
of	O
aging	O
and	O
diabetes	O
.	O

M154	O
the	O
relationship	O
of	O
plasminogen	BG
activator	IG
inhibitor	IG
type	IG
-	IG
1-9	IG
to	O
obesity-11	BP
provides	O
a	O
potential	O
link	O
between	O
the	O
metabolic	O
syndrome	O
and	O
hypercoagulabilty	O
.	O

M155	O
animal	O
studies	O
have	O
shown	O
that	O
overexpression	O
of	O
angiotesinogen	BG
results-9	IG
in	O
hypertension-11	BP
while	O
under	O
expression	O
of	O
angiotesinogen	O
results	O
in	O
decreased	O
blood	O
pressures	O
[	O
22	O
]	O
.	O

M159	O
etiology	O
nevoid	O
basal	BP
cell	IP
carcinoma-5	IP
syndrome	O
is	O
a	O
hereditary	O
condition	O
caused	O
by	O
mutations	O
in	O
the	O
ptch1	BG
gene-17	IG
and	O
is	O
transmitted	O
in	O
an	O
autosomal	O
dominant	O
manner	O
with	O
high	O
penetrance	O
and	O
variable	O
expressivity	O
[	O
93	O
,	O
94	O
]	O
.	O

M160	O
several	O
mutations	O
of	O
the	O
ptch1	BG
gene-6	IG
have	O
been	O
in	O
the	O
radiation	O
fieldtified	O
in	O
patients	O
with	O
nevoid	O
basal	BP
cell	IP
carcinoma	IP
syndrome-20	IP
[	O
101	O
-	O
118	O
]	O
,	O
and	O
,	O
in	O
those	O
with	O
basal	O
cell	O
carcinomas	O
and	O
medulloblastomas-36	BP
that	O
are	O
apparently	O
not	O
hereditary	O
[	O
119	O
,	O
120	O
]	O
.	O

M167	O
vitamin	O
a	O
analogs	O
,	O
such	O
as	O
retinoids	O
,	O
including	O
isotretinoin-10	BG
,	O
may	O
play	O
an	O
important	O
role	O
in	O
preventing	O
or	O
slowing	O
the	O
development	O
of	O
new	O
basal	BP
cell	IP
carcinomas-27	IP
[	O
140	O
,	O
160	O
-	O
164	O
]	O
.	O

M173	O
mutations	O
in	O
myosin	BG
heavy	IG
chain	IG
7-6	IG
are	O
estimated	O
to	O
account	O
for	O
40	O
50	O
%	O
of	O
the	O
cases	O
of	O
hypertrophic	BP
cardiomyopathy-20	IP
.	O

M174	O
mutational	O
analysis	O
of	O
tropomodulin	BG
2-5	IG
in	O
amyotrophic	BP
lateral	IP
sclerosis-9	IP
5	O
two	O
patients	O
and	O
two	O
controls	O
from	O
a	O
family	O
with	O
an	O
autosomal	O
recessive	O
form	O
of	O
familial	O
als	O
(	O
amyotrophic	BP
lateral	IP
sclerosis-30	IP
5	O
)	O
were	O
analyzed	O
for	O
mutations	O
in	O
tropomodulin	BG
2-39	IG
.	O

M177	O
recently	O
,	O
the	O
translin	BG
-	IG
associated	IG
factor	IG
x	IG
gene-9	IG
(	O
translin	BG
-	IG
associated	IG
factor	IG
x	IG
gene-16	IG
)	O
was	O
demonstrated	O
to	O
intergenically	O
splice	O
into	O
disrupted	O
in	O
schizophrenia-26	BP
gene	O
1	O
(	O
disrupted	O
in	O
schizophrenia-32	BP
gene	O
1	O
)	O
.	O

M182	O
in	O
analogy	O
to	O
the	O
pathobiochemical	O
findings	O
in	O
duchenne	O
muscular	BP
dystrophy-10	IP
[	O
,	O
]	O
,	O
the	O
dystrophic	O
animal	O
model	O
mdx	O
mouse	O
also	O
exhibits	O
a	O
drastic	O
reduction	O
in	O
all	O
dystrophin	BG
-	IG
associated	IG
glycoproteins-31	IG
in	O
bulk	O
skeletal	O
muscle	O
[	O
,	O
]	O
.	O

M218	O
two	O
smaller	O
studies	O
,	O
however	O
,	O
yielded	O
contradictory	O
results	O
,	O
as	O
they	O
found	O
that	O
hepatic	O
expressions	O
of	O
adiponectin	BG
mrna-19	IG
and	O
adipor2	BG
receptor-22	IG
were	O
significantly	O
lower	O
in	O
non	O
-	O
alcoholic	O
steatohepatitis	O
patients	O
compared	O
with	O
patients	O
with	O
fatty	BP
liver-37	IP
[	O
81	O
,	O
82	O
]	O
.	O

M227	O
finally	O
,	O
a	O
humanized	O
interleukin	BG
-	IG
6	IG
receptor	IG
antibody-9	IG
,	O
tocilizumab	O
,	O
has	O
been	O
developed	O
and	O
successfully	O
used	O
in	O
patients	O
with	O
rheumatoid	BP
arthritis-23	IP
[	O
98	O
]	O
.	O

M243	O
the	O
effectiveness	O
of	O
this	O
drug	O
in	O
blocking	O
bcr-8	BG
-	O
abl-10	BG
and	O
c	BG
-	IG
kit	IG
tyrosine	IG
kinases-16	IG
has	O
led	O
to	O
food	O
and	O
drug	O
administration	O
(	O
food	O
and	O
drug	O
administration	O
)	O
approval	O
for	O
the	O
treatment	O
of	O
philadelphia	O
chromosome	O
-	O
positive	O
chronic	BP
myelogenous	IP
leukemia-41	IP
and	O
c	O
-	O
kit	O
-	O
positive	O
gastrointestinal	BP
stromal	IP
tumors-50	IP
.	O

M248	O
the	O
inhibition	O
of	O
growth	O
-	O
related	O
kinases	O
,	O
especially	O
tyrosine	BG
kinases-11	IG
,	O
might	O
provide	O
new	O
tools	O
in	O
the	O
therapy	O
of	O
cancer-21	BP
.	O

M251	O
thus	O
,	O
sti571	O
may	O
exert	O
its	O
effect	O
on	O
pancreatic	BP
cancer-10	IP
cell	O
growth	O
through	O
c	BG
-	IG
kit-16	IG
-	O
independent	O
pathways	O
.	O

M256	O
igf	BG
-	IG
1-3	IG
and	O
its	O
receptor	O
igf1r-7	BG
are	O
also	O
overexpressed	O
in	O
pancreatic	BP
cancer-13	IP
,	O
and	O
they	O
also	O
have	O
the	O
potential	O
to	O
stimulate	O
pancreatic	BP
cancer-24	IP
cell	O
growth	O
.	O

M262	O
the	O
2002	O
task	O
force	O
of	O
the	O
acc-7	BG
/	O
aha-9	BG
/	O
naspe	O
gave	O
a	O
class	O
iia	O
recommendation	O
(	O
weight	O
of	O
evidence	O
in	O
favor	O
of	O
efficacy	O
)	O
to	O
biventricular	O
pacing	O
in	O
medically	O
refractory	O
,	O
symptomatic	O
new	O
york	O
heart	O
association	O
class	O
iii	O
or	O
iv	O
patients	O
with	O
idiopathic	O
dilated	O
or	O
ischemic	O
cardiomyopathy-48	BP
,	O
prolonged	O
qrs	O
interval	O
(	O
130	O
ms	O
)	O
,	O
left	O
ventricular	O
end	O
-	O
diastolic	O
diameter	O
greater	O
than	O
or	O
equal	O
to	O
55	O
mm	O
and	O
ejection	O
fraction	O
less	O
than	O
or	O
equal	O
to	O
30	O
percent	O
.	O

M266	O
case	O
presentation	O
canine	O
serum	O
c	BG
-	IG
reactive	IG
protein-8	IG
(	O
c	BG
-	IG
reactive	IG
protein-13	IG
)	O
was	O
measured	O
serially	O
and	O
blinded	O
during	O
a	O
27	O
-	O
week	O
follow	O
-	O
up	O
period	O
of	O
a	O
case	O
of	O
anaplasma	O
phagocytophilia	O
induced	O
type	O
ii	O
immune	O
-	O
mediated	O
polyarthritis-41	BP
.	O

M268	O
the	O
c	BG
-	IG
reactive	IG
protein-5	IG
was	O
already	O
increased	O
at	O
the	O
first	O
relapses	O
of	O
clinical	O
signs	O
of	O
polyarthritis-17	BP
(	O
day	O
47	O
49	O
and	O
day	O
61	O
95	O
)	O
and	O
c	BG
-	IG
reactive	IG
protein-31	IG
was	O
persistently	O
high	O
during	O
the	O
periods	O
of	O
clinical	O
signs	O
.	O

M269	O
thus	O
,	O
a	O
marked	O
increase	O
in	O
c	BG
-	IG
reactive	IG
protein-10	IG
were	O
observed	O
on	O
two	O
occasions	O
,	O
related	O
to	O
the	O
reappearence	O
of	O
clinical	O
signs	O
of	O
polyarthritis-25	BP
.	O

M271	O
canine	O
serum	O
c	BG
-	IG
reactive	IG
protein-6	IG
has	O
earlier	O
been	O
studied	O
as	O
a	O
marker	O
of	O
disease	O
-	O
activity	O
in	O
osteoarthritis-19	BP
(	O
osteoarthritis-21	BP
)	O
[	O
19	O
]	O
,	O
where	O
only	O
slightly	O
elevated	O
levels	O
were	O
observed	O
.	O

M290	O
ocular	BP
albinism-2	IP
type	O
1	O
is	O
thought	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
biogenesis	O
and	O
maturation	O
of	O
melanosomes	O
through	O
activation	O
of	O
heterotrimeric	BG
g	IG
proteins-24	IG
on	O
the	O
cytoplasmic	O
side	O
of	O
melanosomal	O
membrane	O
.	O

M302	O
individuals	O
with	O
reduced	O
anti	BG
-	IG
proteinase-6	IG
activity	O
as	O
a	O
result	O
of	O
alpha1	BG
-	IG
antitrypsin-14	IG
deficiency	O
,	O
have	O
an	O
increased	O
propensity	O
to	O
develop	O
asthma-23	BP
.	O

M303	O
secretory	O
leukocyte	BG
protease	IG
inhibitor-4	IG
levels	O
were	O
found	O
to	O
be	O
decreased	O
in	O
nasal	O
secretion	O
after	O
antigen	O
challenge	O
in	O
vivo	O
as	O
well	O
as	O
in	O
bronchial	O
alveolar	O
lavage	O
obtained	O
from	O
asthmatics-28	BP
compared	O
to	O
healthy	O
subjects	O
.	O

M314	O
contents	O
of	O
antinuclear	BP
antibodies-4	IP
(	O
antinuclear	BP
antibodies-7	IP
)	O
,	O
rheumatoid	BG
factor-11	IG
(	O
rheumatoid	BG
factor-14	IG
)	O
,	O
tumor	BG
necrosis	IG
factor-19	IG
(	O
tnf-21	BG
-	O
)	O
and	O
interleukin	BG
-	IG
6-27	IG
(	O
interleukin	BG
-	IG
6-31	IG
)	O
were	O
measured	O
in	O
serum	O
from	O
20	O
dogs	O
with	O
immune	O
-	O
mediated	O
fever-44	BP
.	O

M320	O
the	O
results	O
of	O
the	O
antinuclear	BP
antibodies-6	IP
,	O
anti	BG
extractable	IG
nuclear	IG
antigens-11	IG
,	O
rheumatoid	BG
factor-14	IG
and	O
interleukin	BG
-	IG
6-18	IG
analyses	O
are	O
presented	O
in	O
table	O
1	O
.	O

M349	O
conclusion	O
results	O
obtained	O
from	O
our	O
analysis	O
in	O
polycystic	BP
ovary-9	IP
syndrome	O
women	O
and	O
this	O
population	O
-	O
based	O
study	O
suggest	O
that	O
calpain	BG
5	IG
gene-22	IG
is	O
a	O
gene	O
related	O
to	O
metabolic	O
syndrome	O
and	O
related	O
phenotypes	O
such	O
as	O
obesity-35	BP
,	O
hypertension-37	BP
and	O
hypercholesterolemia-39	BP
,	O
at	O
least	O
in	O
the	O
spanish	O
population	O
.	O

M375	O
we	O
then	O
examined	O
genetic	O
polymorphisms	O
in	O
four	O
candidate	O
genes	O
(	O
drd4-11	BG
,	O
dat-13	BG
,	O
catecholamine	BG
-	IG
o	IG
-	IG
methyl	IG
transferase-20	IG
and	O
monoamine	BG
oxidase-23	IG
)	O
that	O
have	O
been	O
shown	O
to	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
various	O
psychiatric	BP
disorders-38	IP
where	O
attention	O
is	O
disrupted	O
.	O

M376	O
as	O
an	O
initial	O
assessment	O
of	O
this	O
approach	O
,	O
we	O
chose	O
four	O
candidate	O
genes	O
(	O
drd4-15	BG
,	O
dat1-17	BG
,	O
catecholamine	BG
-	IG
o	IG
-	IG
methyl	IG
transferase-24	IG
and	O
monoamine	BG
oxidase-27	IG
)	O
that	O
are	O
among	O
the	O
most	O
widely	O
studied	O
and	O
repeatedly	O
associated	O
with	O
various	O
psychiatric	BP
disorders-42	IP
where	O
attention	O
is	O
found	O
to	O
be	O
disrupted	O
.	O

M395	O
the	O
functional	O
loss	O
of	O
acetylcholine	BG
receptors-6	IG
reduces	O
the	O
probability	O
of	O
successful	O
neuromuscular	O
transmission	O
following	O
quantal	O
release	O
of	O
acetylcholine	O
by	O
the	O
motor	O
nerve	O
terminal	O
,	O
resulting	O
in	O
clinical	O
weakness-28	BP
in	O
striated	O
muscles	O
.	O

M398	O
rarely	O
,	O
false	O
positive	O
results	O
in	O
acetylcholine	BG
receptor	IG
binding	IG
antibody-10	IG
assays	O
have	O
been	O
observed	O
in	O
patients	O
with	O
other	O
autoimmune	BP
diseases-20	IP
such	O
as	O
systemic	BP
lupus	IP
erythematosus-25	IP
,	O
rheumatoid	BP
arthritis-28	IP
,	O
and	O
inflammatory	O
neuropathy-32	BP
.	O

M407	O
the	O
roles	O
for	O
acetylcholinesterase-4	BG
inhibitors	O
in	O
myasthenia-7	BP
gravis	O
include	O
treatment	O
of	O
ocular	O
and	O
mild	O
generalized	O
disease	O
,	O
treatment	O
in	O
patients	O
who	O
cannot	O
receive	O
immune	O
suppression	O
,	O
and	O
adjunctive	O
treatment	O
for	O
patients	O
receiving	O
immunotherapy	O
with	O
residual	O
or	O
refractory	O
myasthenic	BP
weakness-39	IP
.	O

M414	O
intravenous	O
immunoglobulin	BG
intravenous	IG
immunoglobulin-4	IG
has	O
been	O
utilized	O
in	O
a	O
number	O
of	O
autoimmune	O
neuromuscular	O
disorders	O
including	O
acute	O
and	O
chronic	O
inflammatory	O
polyneuropathy-20	BP
.	O

M421	O
preoperative	O
plasma	O
exchange	O
or	O
intravenous	O
immunoglobulin-6	BG
is	O
performed	O
to	O
improve	O
strength	O
in	O
patients	O
with	O
moderate	O
or	O
severe	O
generalized	O
or	O
bulbar	O
myasthenia-21	BP
gravis	O
or	O
in	O
patients	O
with	O
myasthenia-27	BP
gravis	O
-	O
related	O
respiratory	BP
insufficiency-32	IP
[	O
87	O
]	O
.	O

M447	O
measurement	O
of	O
cardiac	O
troponin-4	BG
can	O
be	O
useful	O
as	O
a	O
non	O
-	O
invasive	O
method	O
to	O
determine	O
suspected	O
myocardial	O
injury	O
,	O
for	O
example	O
in	O
cases	O
presented	O
with	O
cardiac	BP
arrhythmia-27	IP
,	O
severe	O
depression-30	BP
or	O
multi	O
organ	O
dysfunctions	O
.	O

M451	O
still	O
,	O
cardiac	O
troponin	BG
i-5	IG
analysis	O
has	O
been	O
demonstrated	O
to	O
be	O
useful	O
in	O
identifying	O
myocardial	O
injury	O
in	O
human	O
renal	BP
failure-20	IP
patients	O
without	O
overt	O
cardiac	O
disease	O
[	O
38	O
]	O
.	O
